Heterocyclic compounds as immunomodulators
By inhibiting the PD-1/PD-L1 interaction compounds, blocking the PD-1 signaling pathway, the problem of insufficient immune system response in the prior art is solved, and effective treatment of cancer and infectious diseases is achieved.
Patent Information
- Application Number
- CN201980033784.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-06-21
- Filing Date
- 2019-03-29
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2039-03-29
AI Technical Summary
Existing treatments are difficult to effectively block PD-1/PD-L1 protein interactions, resulting in insufficient response of the immune system to cancer and infectious diseases.
A compound is provided that blocks the PD-1 signaling pathway by inhibiting PD-1/PD-L1 interactions, thereby enhancing an immune response. This compound is used in the treatment of cancer and infectious diseases, by inhibiting PD-1/PD-L1 protein interactions and enhancing the immune response.
Effectively block PD-1 signaling pathway, enhance immune response, develop therapeutic effects on cancer and infectious diseases, and improve the activation and proliferation of cancer cells and virus-specific T cells.
Smart Images

Figure CN112135824B_ABST
Abstract
Description
[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 650,821, filed on March 30, 2018, and U.S. Provisional Application No. 62 / 687,964, filed on June 21, 2018, each of which is incorporated herein by reference in its entirety. Field of the Invention
[0002] The present application relates to pharmaceutically active compounds. The present disclosure provides compounds and compositions and methods of use thereof. The compounds modulate PD-1 / PD-L1 protein / protein interactions and can be used to treat a variety of diseases including infectious diseases and cancer. Background of the Invention
[0004] The immune system plays an important role in controlling and eradicating diseases such as cancer. However, cancer cells often develop strategies to evade or suppress the immune system to facilitate their growth. One such mechanism is to change the expression of co-stimulatory and co-inhibitory molecules expressed on immune cells (Postow et al., J.Clinical Oncology 2015, 1-9). It has been shown that blocking the signaling of immune checkpoints such as PD-1 is a promising and effective treatment mode.
[0005] Programmed cell death protein-1 (PD-1), also known as CD279, is a cell surface receptor expressed on activated T cells, natural killer T cells, B cells and macrophages (Greenwald et al., Annu. Rev. Immunol 2005, 23: 515-548; Okazaki and Honjo, Trends Immunol 2006, (4): 195-201). It acts as an internal negative feedback system to prevent T cell activation, which in turn reduces autoimmunity and promotes self-tolerance. In addition, PD-1 is also known to play a key role in suppressing antigen-specific T cell responses in diseases such as cancer and viral infections (Sharpe et al., Nat Immunol 2007 8, 239-245; Postow et al., J. Clinical Oncol 2015, 1-9).
[0006] The structure of PD-1 consists of an extracellular immunoglobulin variable-like domain, followed by a transmembrane region and an intracellular domain (Parry et al., Mol Cell Biol 2005, 9543-9553). The intracellular domain contains two phosphorylation sites located in an immunoreceptor tyrosine-based inhibitory motif and an immunoreceptor tyrosine-based conversion motif, which indicates that PD-1 negatively regulates T cell receptor-mediated signals. PD-1 has two ligands, PD-L1 and PD-L2 (Parry et al., Mol Cell Biol 2005, 9543-9553; Latchman et al., Nat Immunol 2001, 2, 261-268), and the difference between the ligands is their expression pattern. On macrophages and dendritic cells, PD-L1 protein is upregulated in response to lipopolysaccharide and GM-CSF treatment, while on T cells and B cells, it is upregulated after T cell receptor and B cell receptor signaling. PD-L1 is also highly expressed on almost all tumor cells, and the expression is further increased after IFN-γ treatment (Iwai et al., PNAS 2002, 99(19): 12293-7; Blank et al., Cancer Res 2004, 64(3): 1140-5). In fact, tumor PD-L1 expression status has been shown to be prognostic in a variety of tumor types (Wang et al., Eur J Surg Oncol 2015; Huang et al., Oncol Rep 2015; Sabatier et al., Oncotarget 2015, 6(7): 5449-5464). In contrast, PD-L2 expression is more restricted and is mainly expressed by dendritic cells (Nakae et al., J Immunol 2006, 177: 566-73). Ligation of PD-1 with its ligands PD-L1 and PD-L2 on T cells delivers signals that inhibit IL-2 and IFN-γ production and cell proliferation induced by T cell receptor activation (Carter et al., Eur J Immunol 2002, 32(3):634-43; Freeman et al., J Exp Med 2000, 192(7):1027-34). The mechanism involves recruiting SHP-2 or SHP-1 phosphatases to inhibit T cell receptor signaling, such as Syk and Lck phosphorylation (Sharpe et al., Nat Immunol 2007, 8, 239-245).Activation of the PD-1 signaling axis also attenuates PKC-θ activation loop phosphorylation, which is required for activation of the NF-κB and AP1 pathways and production of cytokines such as IL-2, IFN-γ, and TNF (Sharpe et al., Nat Immunol 2007, 8, 239-245; Carter et al., Eur J Immunol 2002, 32(3):634-43; Freeman et al., J Exp Med 2000, 192(7):1027-34).
[0007] Several lines of evidence from preclinical animal studies indicate that PD-1 and its ligands negatively regulate immune responses. Mice lacking PD-1 have been shown to develop lupus-like glomerulonephritis and dilated cardiomyopathy (Nishimura et al., Immunity 1999, 11: 141-151; Nishimura et al., Science 2001, 291: 319-322). Using the LCMV chronic infection model, it has been demonstrated that the PD-1 / PD-L1 interaction inhibits the activation, amplification and acquisition of effector functions of virus-specific CD8 T cells (Barber et al., Nature 2006, 439, 682-7). Overall, these data support the development of therapeutic approaches that block PD-1-mediated inhibitory signaling cascades to enhance or "rescue" T cell responses. Therefore, new compounds that block PD-1 / PD-L1 protein / protein interactions are needed. Summary of the invention
[0008] The present disclosure particularly provides a compound of formula (I'),
[0009]
[0010] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the constituent variables are defined herein.
[0011] The present invention also provides a compound of formula (I):
[0012]
[0013] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the constituent variables are defined herein.
[0014] The present invention also provides a pharmaceutical composition comprising the compound disclosed herein or a pharmaceutically acceptable salt or stereoisomer thereof and one or more pharmaceutically acceptable excipients or carriers.
[0015] The present invention also provides a method for inhibiting PD-1 / PD-L1 interaction, which comprises administering to a patient a compound disclosed herein or a pharmaceutically acceptable salt or stereoisomer thereof.
[0016] The present invention also provides a method for treating a disease or condition associated with the inhibition of PD-1 / PD-L1 interaction, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt or stereoisomer thereof.
[0017] The present invention also provides a method of enhancing, stimulating and / or increasing an immune response in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt or stereoisomer thereof. DETAILED DESCRIPTION
[0018] I. Compounds
[0019] The present disclosure provides, inter alia, compounds of formula (I'):
[0020]
[0021] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0022] Ring A is azetidinyl, pyrrolidinyl or piperidinyl;
[0023] X 1 is CH or N;
[0024] R 1 is methyl or halogen;
[0025] R 2 C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogen alkyl, C 1-4 Halogen alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-2 Alkyl-, OH, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 alkyl)2, 4 to 6 membered heterocycloalkyl or 4 to 6 membered heterocycloalkyl-C 1-2 alkyl-, wherein the 4 to 6 membered heterocycloalkyl and the 4 to 6 membered heterocycloalkyl-C 1-2 Alkyl- each having one or two heteroatoms selected from O and N as ring atoms, and wherein R 2 The C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C1-2 Alkyl-, -NH-C 1-4 Alkyl, -N(C 1-4 alkyl)2, 4 to 6 membered heterocycloalkyl and 4 to 6 membered heterocycloalkyl-C 1-2 Alkyl- each optionally substituted with 1 or 2 substituents independently selected from halo, CN and OH;
[0026] R 3 is selected from the group consisting of (R)-3-hydroxy-3-methylpyrrolidin-1-yl, (S)-3-hydroxy-3-methylpyrrolidin-1-yl, (R)-3-hydroxypyrrolidin-1-yl, (S)-3-hydroxypyrrolidin-1-yl, (R)-2-hydroxy-2-methyl-ethylamino, (S)-2-hydroxy-2-methyl-ethylamino, (R)-2-hydroxy-1-methyl-ethylamino and (S)-2-hydroxy-1-methyl-ethylamino; and
[0027] R 4 H or C 1-3 Alkyl; and
[0028] R 5 It is C(O)OH, C(O)N(CH3)2, C(O)NH(CH3) or C(O)NH(CH2)2C(O)OH.
[0029] In some embodiments, provided herein are compounds of formula (I):
[0030]
[0031] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0032] Ring A is azetidinyl, pyrrolidinyl or piperidinyl;
[0033] X 1 is CH or N;
[0034] R 1 is methyl or halogen;
[0035] R 2 C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogen alkyl, C 1-4 Halogen alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-2 Alkyl-, OH, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 alkyl)2, 4 to 6 membered heterocycloalkyl or 4 to 6 membered heterocycloalkyl-C 1-2alkyl-, wherein the 4 to 6 membered heterocycloalkyl and the 4 to 6 membered heterocycloalkyl-C 1-2 Alkyl- each having one or two heteroatoms selected from O and N as ring atoms, and wherein R 2 The C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-2 Alkyl-, -NH-C 1-4 Alkyl, -N(C 1-4 alkyl)2, 4 to 6 membered heterocycloalkyl and 4 to 6 membered heterocycloalkyl-C 1-2 Alkyl- each optionally substituted with 1 or 2 substituents independently selected from halo, CN and OH;
[0036] R 3 is selected from the group consisting of (R)-3-hydroxy-3-methylpyrrolidin-1-yl, (S)-3-hydroxy-3-methylpyrrolidin-1-yl, (R)-3-hydroxypyrrolidin-1-yl, (S)-3-hydroxypyrrolidin-1-yl, (R)-2-hydroxy-2-methyl-ethylamino, (S)-2-hydroxy-2-methyl-ethylamino, (R)-2-hydroxy-1-methyl-ethylamino and (S)-2-hydroxy-1-methyl-ethylamino; and
[0037] R 4 H or C 1-3 alkyl.
[0038] In some embodiments, Ring A is pyrrolidinyl. In some embodiments, Ring A is piperidinyl. In other embodiments, Ring A is piperidinyl.
[0039] In some embodiments, part Selected from 4-carboxypiperidin-1-yl, 3-carboxypyrrolidin-1-yl, 3-methyl-3-carboxypyrrolidin-1-yl, 4-(N,N-dimethylaminocarbonyl)piperidin-1-yl, 4-(N-methylaminocarbonyl)piperidin-1-yl and 4-(2-carboxyethylaminocarbonyl)piperidin-1-yl, wherein the wavy line indicates the point of attachment to the rest of the molecule.
[0040] In some embodiments, part Selected from 4-carboxypiperidin-1-yl, 3-carboxypyrrolidin-1-yl, and 3-methyl-3-carboxypyrrolidin-1-yl, wherein the wavy line indicates the point of attachment to the rest of the molecule.
[0041] In some embodiments, part is 4-carboxypiperidin-1-yl, where the wavy line indicates the point of attachment to the rest of the molecule.
[0042] In some embodiments, part In some embodiments, 3-carboxypyrrolidin-1-yl is (R)-3-carboxypyrrolidin-1-yl, wherein the wavy line indicates the point of attachment to the rest of the molecule. In some embodiments, 3-carboxypyrrolidin-1-yl is (R)-3-carboxypyrrolidin-1-yl. In some embodiments, 3-carboxypyrrolidin-1-yl is (S)-3-carboxypyrrolidin-1-yl.
[0043] In some embodiments, part Selected from 4-(N,N-dimethylaminocarbonyl)piperidin-1-yl, 4-(N-methylaminocarbonyl)piperidin-1-yl and 4-(2-carboxyethylaminocarbonyl)piperidin-1-yl, wherein the wavy line indicates the point of attachment to the rest of the molecule.
[0044] In some embodiments, part In some embodiments, 3-methyl-3-carboxypyrrolidin-1-yl is (R)-3-methyl-3-carboxypyrrolidin-1-yl, wherein the wavy line indicates the point of attachment to the rest of the molecule. In some embodiments, 3-methyl-3-carboxypyrrolidin-1-yl is (R)-3-methyl-3-carboxypyrrolidin-1-yl. In some embodiments, 3-methyl-3-carboxypyrrolidin-1-yl is (S)-3-methyl-3-carboxypyrrolidin-1-yl.
[0045] In some embodiments, part Selected from 4-carboxypiperidin-1-yl, (R)-3-carboxypyrrolidin-1-yl, (S)-3-carboxypyrrolidin-1-yl, (R)-3-methyl-3-carboxypyrrolidin-1-yl and (S)-3-methyl-3-carboxypyrrolidin-1-yl, wherein the wavy line indicates the point of attachment to the rest of the molecule.
[0046] In some embodiments, X 1 is N. In some embodiments, X 1 For CH.
[0047] In some embodiments, R 1 is CH3 or Cl. In some embodiments, R 1 is CH3. In some embodiments, R 1 is halo (eg, F, Cl, or Br). 1 For Cl.
[0048] In some embodiments, R 2 C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogen alkyl, C 1-4 Halogen alkoxy, C 3-6 Cycloalkyl, C 3-6Cycloalkyl-C 1-2 Alkyl-, OH, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 alkyl)2, 1-azetidinyl, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-ylmethyl, 1-piperidinyl or piperidin-1-ylmethyl, wherein R 2 The C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-2 Alkyl-, -NH-C 1-4 Alkyl, -N(C 1-4 alkyl)2, 1-azetidinyl, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-ylmethyl, 1-piperidinyl and piperidin-1-ylmethyl are each optionally substituted with 1 or 2 substituents independently selected from halo, CN and OH.
[0049] In some embodiments, R 2 C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogen alkyl, C 1-4 Halogen alkoxy, OH, NH2, -NH-C 1-4 Alkyl or -N(C 1-4 alkyl)2, wherein R 2 The C 1-4 Alkyl, C 1-4 Alkoxy, -NH-C 1-4 Alkyl and -N(C 1-4 alkyl)2 are each optionally substituted with 1 or 2 substituents independently selected from halo, CN and OH.
[0050] In some embodiments, R 2 C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-2 alkyl-, 1-azetidinyl, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-ylmethyl, 1-piperidinyl or piperidin-1-ylmethyl, wherein R 2 The C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-2 Alkyl-, 1-azetidinyl, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-ylmethyl, 1-piperidinyl and piperidin-1-ylmethyl are each optionally substituted with 1 or 2 substituents independently selected from halo, CN and OH.
[0051] In some embodiments, R 2 is methyl, ethyl, isopropyl, methoxy, ethoxy, CF3, CHF2, CFH2, OCF3, OCHF2, OCH2F, cyclopropyl, cyclobutyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, OH, NH2, NHCH3, N(CH3)2, 1-azetidinyl, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-ylmethyl, 1-piperidinyl or piperidin-1-ylmethyl, wherein R 2 The methyl, ethyl, isopropyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, NHCH3, N(CH3)2, 1-azetidinyl, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-ylmethyl, 1-piperidinyl and piperidin-1-ylmethyl are each optionally substituted with 1 or 2 substituents independently selected from F, Cl, Br, CN and OH.
[0052] In some embodiments, R 2 is methyl, ethyl, isopropyl, methoxy, ethoxy, CF3, CHF2, CFH2, OCF3, OCHF2, OCH2F, OH, NH2, NHCH3 or N(CH3)2, wherein R 2 The methyl, ethyl, isopropyl, methoxy, ethoxy, NHCH3 and N(CH3)2 are each optionally substituted with 1 or 2 substituents independently selected from F, Cl, Br, CN and OH.
[0053] In some embodiments, R 2 is cyclopropyl, cyclobutyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, 1-azetidinyl, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-ylmethyl, 1-piperidinyl or piperidin-1-ylmethyl, wherein R 2 The cyclopropyl, cyclobutyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, 1-azetidinyl, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-ylmethyl, 1-piperidinyl and piperidin-1-ylmethyl are each optionally substituted with 1 or 2 substituents independently selected from F, Cl, Br, CN and OH.
[0054] In some embodiments, R 2 It is CH3, CF3, CHF2, CH(CH3)2, NH2, cyclopropyl or CH2OH.
[0055] In some embodiments, R 2 C 1-4 Alkyl or C 1-4Haloalkyl, each of which is optionally substituted with 1 or 2 substituents independently selected from F, Cl, Br, CN and OH.
[0056] In some embodiments, R 2 C 1-4 Alkyl or C 1-4 In some embodiments, R 2 is CH3, CF3, CHF2 or CH(CH3)2. In some embodiments, R 2 C 1-4 Alkyl, such as CH3 and CH(CH3)2. In some embodiments, R 2 is CH3. In some embodiments, R 2 is CH(CH3)2. In some embodiments, R 2 C 1-4 haloalkyl, such as CF3, CHF2 and CH2F. In some embodiments, R 2 C 1-4 haloalkyl, such as CF3 and CHF2. 2 is CF3. In some embodiments, R 2 is CHF2. In some embodiments, R 2 is CH2F.
[0057] In some embodiments, R 2 is NH2, NHCH3 or N(CH3)2, wherein R 2 The NHCH3 and N(CH3)2 are each optionally substituted with 1 or 2 substituents independently selected from F, Cl, Br, CN and OH. 2 is NH2.
[0058] In some embodiments, R 2 is cyclopropyl, cyclobutyl or cyclohexyl, wherein R 2 The cyclopropyl, cyclobutyl and cyclohexyl groups are each optionally substituted with 1 or 2 substituents independently selected from F, Cl, Br, CN and OH. 2 is cyclopropyl optionally substituted with 1 or 2 substituents independently selected from F, Cl, Br, CN and OH. 2 It is cyclopropyl.
[0059] In some embodiments, R 3 is (R)-3-hydroxy-3-methylpyrrolidin-1-yl or (S)-3-hydroxy-3-methylpyrrolidin-1-yl. 3is (R)-3-hydroxypyrrolidin-1-yl or (S)-3-hydroxypyrrolidin-1-yl. In some embodiments, R 3 is (R)-2-hydroxy-2-methyl-ethylamino or (S)-2-hydroxy-2-methyl-ethylamino. 3 It is (R)-2-hydroxy-1-methyl-ethylamino or (S)-2-hydroxy-1-methyl-ethylamino.
[0060] In some embodiments, R 4 is H or CH3. In some embodiments, R 4 is H. In some embodiments, R 4 C 1-3 Alkyl, such as CH3.
[0061] In some embodiments, the compounds provided herein are compounds of Formula II:
[0062]
[0063] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 , R 3 , R 4 and Ring A are as described herein.
[0064] In some embodiments, the compound provided herein is a compound of Formula III:
[0065]
[0066] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 , R 3 and Ring A are as described herein.
[0067] In some embodiments, the compound provided herein is a compound of Formula IV:
[0068]
[0069] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 , R 3 , R 4 and Ring A are as described herein.
[0070] In some embodiments, the compounds provided herein are compounds of Formula V:
[0071]
[0072] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 , R 3and Ring A are as described herein.
[0073] In some embodiments, the compound is selected from:
[0074] 1-((7-cyano-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;
[0075] 1-((7-cyano-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;
[0076] 1-((7-cyano-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;
[0077] 1-((7-cyano-2-(3′-(7-((1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;
[0078] 1-((7-cyano-2-(3′-(7-((2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;
[0079] 1-((7-cyano-2-(3′-(7-((-3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0080] 1-((7-cyano-2-(3′-(7-((-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0081] 1-((7-cyano-2-(3′-(7-((-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0082] 1-((7-cyano-2-(3′-(7-((-1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0083] 1-((7-cyano-2-(3′-(7-((-2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0084] 1-((7-cyano-2-(3′-(7-((-3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;
[0085] 1-((7-cyano-2-(3′-(7-((-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;
[0086] 1-((7-cyano-2-(3′-(7-((-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;
[0087] 1-((7-cyano-2-(3′-(7-((-1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;
[0088] 1-((7-cyano-2-(3′-(7-((-2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;
[0089] 1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;
[0090] 1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0091] 1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;
[0092] 1-((7-cyano-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;
[0093] 1-((7-cyano-2-(3′-(7-((-3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; and
[0094] 1-((7-cyano-2-(3′-(7-((-3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid,
[0095] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0096] In some embodiments, the compound is selected from:
[0097] 1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0098] 1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;
[0099] 1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-4-methylpiperidine-4-carboxylic acid;
[0100] 1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-N,N-dimethylpiperidine-4-carboxamide;
[0101] 1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-N-methylpiperidine-4-carboxamide;
[0102] 3-(1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxamido)propanoic acid;
[0103] 1-((7-cyano-2-(3′-(2-cyclopropyl-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0104] 1-((2-(3′-(2-amino-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)-7-cyanobenzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;
[0105] 1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;
[0106] 1-((7-cyano-2-(3′-(2-(hydroxymethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;
[0107] 1-((7-cyano-2-(3′-(3-((3-hydroxypyrrolidin-1-yl)methyl)-6-methyl-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; and
[0108] 1-((7-cyano-2-(3′-(6-(difluoromethyl)-3-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid,
[0109] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0110] In some embodiments, the compound is selected from the examples provided herein.
[0111] It is further understood that, for clarity, certain features of the invention described in the context of separate embodiments may also be provided in combination in a single embodiment (where the embodiments are intended to be written as general combinations in multiple dependent forms). Conversely, for simplicity, various features of the invention described in the context of a single embodiment may also be provided separately or in any suitable subcombination. Thus, it is contemplated that the features of the embodiments described as compounds of formula (I) may be combined in any suitable combination.
[0112] At various places in this specification, certain features of compounds are disclosed as groups or in ranges. It is specifically intended that such disclosure includes every individual subcombination of the members of such groups and ranges. For example, the term "C 1-6The term "alkyl" is specifically intended to disclose individually, without limitation, methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl.
[0113] The term "n-membered" where n is an integer generally describes the number of ring atoms in a moiety having a number of ring atoms of n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaromatic ring, pyridinyl is an example of a 6-membered heteroaromatic ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl.
[0114] At various places in this specification, variables defining a divalent linking group may be described. It is specifically intended that each linking substituent include both the forward and reverse forms of the linking substituent. For example, -NR(CR'R") n -Including-NR(CR′R″) n -with-(CR′R″) n NR-, and each individual form is intended to be disclosed. Where a structure requires a linking group, the Markush variable listed for that group is to be understood as the linking group. For example, if a structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl," it is to be understood that "alkyl" or "aryl" means a linking alkylene or arylene, respectively.
[0115] The term "substituted" means that an atom or a group of atoms replaces hydrogen formally as a "substituent" attached to another group. Unless otherwise indicated, the term "substituted" refers to any degree of substitution, such as monosubstituted, disubstituted, trisubstituted, tetrasubstituted or pentasubstituted (where such substitution is allowed). Substituents are independently selected, and substitution can be carried out at any chemically feasible position. It should be understood that substitution on a given atom is limited by valence. It should be understood that substitution on a given atom produces chemically stable molecules. The phrase "optionally substituted" means unsubstituted or substituted. The term "substituted" means removing a hydrogen atom and being replaced by a substituent. A single divalent substituent (such as an oxo group) can replace two hydrogen atoms.
[0116] The term "C n-m " indicates a range including the endpoint, where n and m are integers and indicate the number of carbons. Examples include C 1-4 , C 1-6 etc.
[0117] The term "alkyl" used alone or in combination with other terms refers to a saturated hydrocarbon group which may be straight chain or branched. n-m"Alkyl" refers to an alkyl group having n to m carbon atoms. Alkyl formally corresponds to an alkane in which one CH bond is replaced by the point of attachment of the alkyl group to the rest of the compound. In some embodiments, the alkyl group contains 1 to 6 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl; higher homologs such as 2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl, and the like.
[0118] The term "alkenyl", used alone or in combination with other terms, refers to a straight or branched hydrocarbon radical corresponding to an alkyl radical having one or more carbon-carbon double bonds. Alkenyl formally corresponds to an alkene in which one CH bond is replaced by the point of attachment of the alkenyl radical to the rest of the compound. n-m "Alkenyl" refers to an alkenyl group having n to m carbon atoms. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms. Examples of alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like.
[0119] The term "alkynyl", used alone or in combination with other terms, refers to a straight or branched hydrocarbon radical corresponding to an alkyl radical having one or more carbon-carbon triple bonds. Alkynyl formally corresponds to an alkyne in which one CH bond is replaced by an alkyl radical at the point of attachment to the rest of the compound. n-m "Alkynyl" refers to an alkynyl group having n to m carbons. Examples of alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
[0120] The term "alkylene", used alone or in combination with other terms, refers to a divalent alkyl linking group. Alkylene formally corresponds to an alkane with two CH bonds replaced by the points of attachment of the alkylene group to the rest of the compound. n-m “Alkylene” refers to an alkylene radical having n to m carbon atoms. Examples of alkylene radicals include, but are not limited to, ethane-1,2-diyl, propane-1,3-diyl, propane-1,2-diyl, butane-1,4-diyl, butane-1,3-diyl, butane-1,2-diyl, 2-methyl-propane-1,3-diyl, and the like.
[0121] The term "alkoxy", used alone or in combination with other terms, refers to a radical of the formula -O-alkyl, wherein alkyl is as defined above. n-m"Alkoxy" refers to an alkoxy group in which the alkyl group has n to m carbons. Examples of alkoxy groups include methoxy, ethoxy, propoxy (eg, n-propoxy and isopropoxy), tert-butoxy, and the like. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0122] The term "amino" refers to a group of formula -NH2.
[0123] The term "carbamyl" refers to a group of formula -C(O)NH2.
[0124] The term "carbonyl," employed alone or in combination with other terms, refers to a -C(=O)- group, which may also be written C(O).
[0125] The term "cyano" or "nitrile" refers to a radical of the formula -C≡N, which may also be written as -CN.
[0126] The term "halo" or "halogen" used alone or in combination with other terms refers to fluorine, chlorine, bromine and iodine. In some embodiments, "halo" refers to a halogen atom selected from F, Cl or Br. In some embodiments, halo is F.
[0127] As used herein, the term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms have been replaced by a halogen atom. n-m "Haloalkyl" refers to a C group having n to m carbon atoms and at least one to at most {2(n to m)+1} halogen atoms. n-m In some embodiments, the halogen atom is a fluorine atom. In some embodiments, the haloalkyl group has 1 to 6 or 1 to 4 carbon atoms. Examples of haloalkyl groups include CF3, C2F5, CHF2, CCl3, CHCl2, C2Cl5, etc. In some embodiments, the haloalkyl group is a fluoroalkyl group.
[0128] The term "haloalkoxy" used alone or in combination with other terms refers to a radical of the formula -O-haloalkyl, wherein haloalkyl is as defined above. n-m "Haloalkoxy" refers to a haloalkoxy group wherein the haloalkyl group has n to m carbons. Examples of haloalkoxy groups include trifluoromethoxy and the like. In some embodiments, the haloalkoxy group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0129] The term "oxo" refers to an oxygen atom as a divalent substituent, forming a carbonyl when attached to carbon, or forming a sulfoxide or sulfone group, or an N-oxide group when attached to a heteroatom. In some embodiments, the heterocyclic group may be optionally substituted with 1 or 2 oxo (=O) substituents.
[0130] The term "sulfonyl" refers to a sulfur atom as a divalent substituent which when attached to carbon forms a thiocarbonyl (C=S).
[0131] The term "aromatic" refers to a carbocyclic or heterocyclic ring having one or more polyunsaturated rings and having aromatic character (ie, having (4n+2) delocalized π (π) electrons, where n is an integer).
[0132] The term "aryl" used alone or in combination with other terms refers to an aromatic hydrocarbon group which may be monocyclic or polycyclic (eg, having two fused rings). n-m "Aryl" refers to an aromatic radical having n to m ring carbon atoms. Aryl includes, for example, phenyl, naphthyl, dihydroindenyl, indenyl, and the like. In some embodiments, the aryl radical has 6 to about 10 carbon atoms. In some embodiments, the aryl radical has 6 carbon atoms. In some embodiments, the aryl radical has 10 carbon atoms. In some embodiments, the aryl radical is phenyl. In some embodiments, the aryl radical is naphthyl.
[0133] As used herein, the term "heteroatom" is meant to include boron, phosphorus, sulfur, oxygen and nitrogen.
[0134] The term "heteroaryl" or "heteroaromatic" used alone or in combination with other terms refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from boron, phosphorus, sulfur, oxygen and nitrogen. In some embodiments, the heteroaromatic ring has 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, any ring-forming N in the heteroaryl moiety may be an N-oxide. In some embodiments, the heteroaryl group has 5-14 ring atoms including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group has 5-14 or 5-10 ring atoms including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaromatic ring has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group is a five-membered or six-membered heteroaromatic ring. In other embodiments, the heteroaryl group is an eight-membered, nine-membered or ten-membered fused bicyclic heteroaromatic ring. Examples of heteroaryl groups include, but are not limited to, pyridinyl (pyridyl), pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, oxazolyl, oxazolyl, thiazolyl, imidazolyl, furanyl, thienyl, quinolyl, isoquinolyl, naphthyridinyl (including 1,2-naphthyridine, 1,3-naphthyridine, 1,4-naphthyridine, 1,5-naphthyridine, 1,6-naphthyridine, 1,7-naphthyridine, 1,8-naphthyridine, 2,3-naphthyridine and 2,6-naphthyridine), indolyl, benzothienyl, benzofuranyl, benzisoxazolyl, imidazo[1,2-b]thiazolyl, purinyl, and the like.
[0135] A five-membered heteroaryl ring is a heteroaryl group having five ring atoms, wherein one or more (e.g., 1, 2, or 3) of the ring atoms are independently selected from N, O, and S. Exemplary five-membered heteroaryl groups include thienyl, furanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl.
[0136] A six-membered heteroaryl ring is a heteroaryl group having six ring atoms, wherein one or more (eg, 1, 2, or 3) of the ring atoms are independently selected from N, O, and S. Exemplary six-membered ring heteroaryl groups are pyridinyl, pyrazinyl, pyrimidinyl, triazinyl, and pyridazinyl.
[0137] The term "cycloalkyl" used alone or in combination with other terms refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic or polycyclic) including cyclized alkyl and alkenyl groups. n-m "Cycloalkyl" refers to a cycloalkyl group having n to m ring member carbon atoms. Cycloalkyl groups may include monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) groups and spirocyclic groups. Cycloalkyl groups may have 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring carbon atoms (C 3-14 ). In some embodiments, the cycloalkyl has 3 to 14 members, 3 to 10 members, 3 to 6 ring members, 3 to 5 ring members, or 3 to 4 ring members. In some embodiments, the cycloalkyl is a monocyclic ring. In some embodiments, the cycloalkyl is a monocyclic ring or a bicyclic ring. In some embodiments, the cycloalkyl is C 3-6 Monocyclic cycloalkyl. The ring-forming carbon atoms of cycloalkyl can be optionally oxidized to form oxo or sulfide groups. Cycloalkyl also includes cycloalkylene. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. The definition of cycloalkyl also includes a portion of an aromatic ring having one or more fused to a cycloalkyl ring (i.e., sharing a key with the cycloalkyl ring), such as benzo or thienyl derivatives of cyclopentane, cyclohexane, etc. The cycloalkyl containing a fused aromatic ring can be attached by any ring-forming atom, including the ring-forming atom of the fused aromatic ring. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarbyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, etc. In some embodiments, the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0138] The term "heterocycloalkyl" used alone or in combination with other terms refers to a non-aromatic ring or ring system that may optionally contain one or more alkenylene groups as part of the ring structure, has at least one heteroatom ring member independently selected from boron, nitrogen, sulfur, oxygen and phosphorus, and has 4-14 ring members, 4-10 ring members, 4-7 ring members or 4-6 ring members. The term "heterocycloalkyl" includes monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyls. Heterocycloalkyls may include monocyclic or bicyclic or polycyclic (e.g., having two or three fused or bridged rings) ring systems or spirocycles. In some embodiments, heterocycloalkyls are monocyclic groups with 1, 2 or 3 heteroatoms independently selected from nitrogen, sulfur and oxygen. The ring-forming carbon atoms and heteroatoms of heterocycloalkyls may be optionally oxidized to form oxo groups or sulfide groups or other oxidative linkages (e.g., C(O), S(O), C(S) or S(O)2, N-oxides, etc.), or nitrogen atoms may be quaternized. Heterocycloalkyl can be attached through ring-forming carbon atoms or ring-forming heteroatoms. In some embodiments, heterocycloalkyl contains 0 to 3 double bonds. In some embodiments, heterocycloalkyl contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties having one or more aromatic rings fused to the heterocycloalkyl ring (i.e., sharing a bond with the heterocycloalkyl ring), such as benzo or thienyl derivatives of piperidine, morpholine, azapine, and the like. Heterocycloalkyl containing fused aromatic rings can be attached through any ring-forming atom, including the ring-forming atom of the fused aromatic ring. Examples of heterocycloalkyl groups include azetidinyl, azepanyl, dihydrobenzofuranyl, dihydrofuranyl, dihydropyranyl, morpholinyl, 3-oxa-9-azaspiro[5.5]undecyl, 1-oxa-8-azaspiro[4.5]decyl, piperidinyl, piperazinyl, oxopiperazinyl, pyranyl, pyrrolidinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydroquinolinyl, tropicanyl, 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridinyl, and thiomorpholinyl.
[0139] In some places, definitions or embodiments refer to specific rings (e.g., azetidine ring, pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member, provided that the number of valences is not exceeded. For example, the azetidine ring can be attached at any position of the ring, while the azetidin-3-yl ring is attached at the 3-position.
[0140] The compounds described herein may be asymmetric (e.g., have one or more stereocenters). Unless otherwise indicated, all stereoisomers such as enantiomers and diastereomers are contemplated. Compounds of the present invention containing asymmetrically substituted carbon atoms can be separated in optically active or racemic forms. Methods for preparing optically active forms from optically inactive starting materials are known in the art, such as by resolving racemic mixtures or by stereoselective synthesis. Many geometric isomers of alkenes, C=N double bonds, etc. may also be present in the compounds described herein, and all such stable isomers are encompassed in the present invention. The cis and trans geometric isomers of the compounds of the present invention are described and can be separated as isomer mixtures or as separate isomers.
[0141] The resolution of the racemic mixture of compound can be carried out by any of many methods known in the art. One method includes using the chiral resolution acid as optically active salified organic acid to carry out fractional recrystallization. The resolving agent suitable for fractional recrystallization is for example optically active acid, for example tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or multiple optically active camphorsulfonic acid (for example β-camphorsulfonic acid) of D and L forms. Other resolving agents suitable for fractional crystallization include the stereoisomerically pure form (for example S and R form, or diastereoisomerically pure form) of alpha-methylbenzylamine, 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane etc.
[0142] The resolution of the racemic mixture can also be carried out by elution on a column packed with an optically active resolving agent (eg dinitrobenzoylphenylglycine). The composition of the suitable elution solvent can be determined by those skilled in the art.
[0143] In some embodiments, the compounds of the invention have an (R)-configuration. In other embodiments, the compounds have an (S)-configuration. In compounds with more than one chiral center, unless otherwise indicated, each chiral center in the compound may independently be (R) or (S).
[0144] Compounds of the present invention also include tautomeric forms. Tautomeric forms are produced by the exchange of single bonds with adjacent double bonds accompanied by proton migration. Tautomeric forms include proton transfer tautomers, which are isomeric protonation states with the same empirical formula and total charge. Proton transfer tautomer examples include keto-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, enamine-imine pairs, and cyclic forms in which protons can occupy two or more positions of heterocyclic systems, such as 1H-imidazole and 3H-imidazole, 1H-1,2,4-triazole, 2H-1,2,4-triazole and 4H-1,2,4-triazole, 1H-isoindole and 2H-isoindole and 1H-pyrazole and 2H-pyrazole. Tautomeric forms can be in equilibrium or spatially locked into a form by appropriate substitution.
[0145] Compounds of the present invention may also include all isotopes of atoms present in intermediates or final compounds. Isotopes include those atoms with the same atomic number but different mass numbers. For example, hydrogen isotopes include tritium and deuterium. One or more constituent atoms of compounds of the present invention may be replaced or substituted by atomic isotopes of natural or non-natural abundance. In some embodiments, compounds include at least one deuterium atom. For example, one or more hydrogen atoms in compounds of the present invention may be replaced or substituted by deuterium. In some embodiments, compounds include two or more deuterium atoms. In some embodiments, compounds include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 deuterium atoms. Synthetic methods for including isotopes in organic compounds are known in the art.
[0146] As used herein, the term "compound" is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the depicted structure. The term also means a compound of the invention, no matter how it is prepared, e.g., by synthesis, by biological methods (e.g., metabolic or enzymatic conversion), or a combination thereof.
[0147] All compounds and pharmaceutically acceptable salts thereof exist together with other substances such as water and solvents (e.g., hydrates and solvates), or may be isolated. When in the solid state, the compounds described herein and their salts may exist in a variety of forms, and may, for example, take the form of solvates, including hydrates. The compound may be in any solid state form, such as a polymorph or solvate, so unless otherwise clearly indicated, reference to the compound and its salt in this specification should be understood to encompass any solid state form of the compound.
[0148] In some embodiments, the compound of the present invention or its salt is substantially isolated. "Substantially isolated" means that the compound is at least partially or substantially separated from the environment in which it is formed or detected. Partial separation may include, for example, a composition enriched with the compound of the present invention. Substantially separating may include a composition containing at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, or at least about 99% by weight of the compound of the present invention or its salt.
[0149] The phrase "pharmaceutically acceptable" as used herein refers to those compounds, substances, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problems or complications, and commensurate with a reasonable benefit / risk ratio.
[0150] The expressions "ambient temperature" and "room temperature" as used herein are understood in the art and generally refer to a temperature, e.g., a reaction temperature, of about the temperature of the room in which the reaction is carried out, e.g., about 20°C to about 30°C.
[0151] The present invention also includes pharmaceutically acceptable salts of the compounds described herein. The term "pharmaceutically acceptable salt" refers to a derivative of a disclosed compound in which the parent compound is modified by converting the acid or base moiety present into its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines; alkali metal or organic salts of acidic residues such as carboxylic acids; and the like. Pharmaceutically acceptable salts of the present invention include, for example, non-toxic salts of the parent compound formed by non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound containing a basic or acidic moiety by conventional chemical methods. In general, such salts can be prepared by reacting the free acid or free base form of these compounds with a stoichiometric amount of an appropriate base or acid in water or an organic solvent or a mixture of the two; in general, non-aqueous media such as ether, ethyl acetate, alcohols (e.g., methanol, ethanol, isopropanol or butanol) or acetonitrile (MeCN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th edition, (Mack Publishing Company, Easton, 1985), page 1418; Berge et al., J. Pharm. Sci., 1977, 66(1), 1-19; and Stahl et al., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (Wiley, 2002). In some embodiments, the compounds described herein include N-oxide forms.
[0152] II. Synthesis
[0153] The compounds of the present invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of a number of possible synthetic routes.
[0154] The reaction for preparing the compound of the present invention can be carried out in a suitable solvent that can be easily selected by a technician in the field of organic synthesis. Suitable solvents may not react substantially with the starting material (reactant), intermediate or product at a temperature for reacting, for example, at a temperature within the range of the solvent freezing temperature to the solvent boiling temperature. A given reaction can be carried out in a solvent or in a mixture of more than one solvent. Depending on the specific reaction steps, a skilled person can select a solvent suitable for the specific reaction steps.
[0155] The preparation of the compounds of the invention may involve the protection and deprotection of a variety of chemical groups. The need for protection and deprotection and the selection of appropriate protecting groups are readily determined by one skilled in the art. Protecting group chemistry is described, for example, in Kocienski, Protecting Groups, (Thieme, 2007); Robertson, Protecting Group Chemistry, (Oxford University Press, 2000); Smith et al., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 6th Edition (Wiley, 2007); Peturssion et al., "Protecting Groups in Carbohydrate Chemistry", J. Chem. Educ., 1997, 74 (11), 1297; and Wuts et al., Protective Groups in Organic Synthesis, 4th Edition, (Wiley, 2006).
[0156] The reaction can be monitored by any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g. 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible spectrophotometry), mass spectrometry or by monitoring by chromatography, such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
[0157] III. Uses of the Compounds
[0158] The compounds of the present disclosure can inhibit the activity of PD-1 / PD-L1 protein / protein interactions and, therefore, can be used to treat diseases and conditions associated with PD-1 activity and diseases and conditions associated with PD-L1, including its interaction with other proteins such as PD-1 and B7-1 (CD80). In certain embodiments, the compounds of the present disclosure or their pharmaceutically acceptable salts or stereoisomers can be used for therapeutic administration to enhance, stimulate and / or increase immunity in cancer, chronic infection or sepsis, including enhancing the response to vaccination. In some embodiments, the present disclosure provides a method for inhibiting PD-1 / PD-L1 protein / protein interactions. The method comprises administering to an individual or patient a compound of formula (I) or any of the formulas described herein, or a compound as described in any of the claims and described herein, or a pharmaceutically acceptable salt or stereoisomer thereof. The compounds of the present disclosure can be used alone, in combination with other agents or therapies, or as adjuvant therapy or neoadjuvant therapy for the treatment of diseases or conditions including cancer or infectious diseases. For the uses described herein, any compound of the present disclosure can be used, including any embodiment thereof.
[0159] The compounds disclosed herein inhibit PD-1 / PD-L1 protein / protein interactions, resulting in PD-1 pathway blockade. Blockade of PD-1 can enhance immune responses to cancer cells and infectious diseases in mammals, including humans. In some embodiments, the present disclosure provides the use of a compound of formula (I) or a salt or stereoisomer thereof to treat an individual or patient in vivo, thereby inhibiting the growth of a cancerous tumor. A compound of formula (I) or any formula as described herein, or a compound as described and described herein as described in any one of the claims, or a salt or stereoisomer thereof, can be used to inhibit the growth of a cancerous tumor. Alternatively, a compound of formula (I) or any formula as described herein, or a compound as described and described herein as described in any one of the claims, or a salt or stereoisomer thereof, can be used in combination with other agents or standard cancer treatments as described below. In one embodiment, the present disclosure provides a method for inhibiting the growth of tumor cells in vitro. The method comprises contacting an in vitro tumor cell with a compound of formula (I) or any formula as described herein, or a compound as described and described herein as described in any one of the claims, or a salt or stereoisomer thereof. In another embodiment, the present disclosure provides a method for inhibiting the growth of tumor cells in an individual or patient. The method comprises administering to an individual or patient in need thereof a therapeutically effective amount of a compound of formula (I) or any formula as described herein, or a compound as recited in any one of the claims and described herein, or a salt or stereoisomer thereof.
[0160] In some embodiments, provided herein is a method for treating cancer. The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the formulas described herein, a compound as described in any one of the claims and as described herein, or a salt thereof. Examples of cancers include cancers whose growth can be inhibited using the compounds disclosed herein and cancers that are generally responsive to immunotherapy.
[0161] In some embodiments, the present disclosure provides a method of enhancing, stimulating and / or increasing an immune response in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the formulas described herein, a compound or composition as described in any of the claims and as described herein, or a salt thereof.
[0162] Examples of cancers that may be treated using the compounds of the present disclosure include, but are not limited to, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, malignant melanoma of the skin or within the eye, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, Disease), non-Hodgkin's disease, esophageal cancer, small intestinal cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, chronic or acute leukemia (including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia), juvenile solid tumors, lymphocytic lymphoma, bladder cancer, kidney or urethral cancer, renal pelvis cancer, central nervous system (CNS) neoplasms, primary CNS lymphoma, tumor angiogenesis, spinal axis tumors, brain stem gliomas, pituitary adenomas, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers (including cancers induced by asbestos) and combinations of the cancers. The compounds of the present disclosure can also be used to treat metastatic cancers, particularly metastatic cancers expressing PD-L1.
[0163] In some embodiments, cancers that can be treated with the compounds of the present disclosure include melanoma (e.g., metastatic malignant melanoma, cutaneous melanoma), renal cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), breast cancer (e.g., invasive breast carcinoma), colon cancer, lung cancer (e.g., non-small cell lung cancer and small cell lung cancer), squamous cell head and neck cancer (e.g., head and neck squamous cell carcinoma), urothelial cancer (e.g., bladder cancer, non-muscle invasive bladder cancer (NMIBC)), and cancer with high microsatellite instability (MSI 高 ) cancers. Additionally, the disclosure includes refractory or recurrent malignancies whose growth can be inhibited using the compounds of the disclosure.
[0164] In some embodiments, cancers that can be treated using the compounds of the present disclosure include, but are not limited to, solid tumors (e.g., prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, kidney cancer, liver cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, head and neck cancer, thyroid cancer, glioblastoma, sarcoma, bladder cancer, etc.), hematological cancers (e.g., lymphoma, leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML)), DLBCL, mantle cell lymphoma, non-Hodgkin lymphoma (including relapsed or refractory NHL and relapsed follicular NHL), Hodgkin lymphoma, or multiple myeloma), and combinations of the aforementioned cancers.
[0165] In some embodiments, cancers that may be treated using the compounds of the present disclosure include, but are not limited to, cholangiocellular carcinoma, bile duct cancer, biliary cancer, triple negative breast cancer, rhabdomyosarcoma, small cell lung cancer, leiomyosarcoma, hepatocellular carcinoma, Ewing's sarcoma, brain cancer, brain tumor, astrocytoma, neuroblastoma, neurofibroma, basal cell carcinoma, chondrosarcoma, epithelioid sarcoma, eye cancer, fallopian tube cancer, gastrointestinal cancer, gastrointestinal stromal tumor, hairy cell leukemia, intestinal cancer, islet cell carcinoma, mouth cancer, oral cancer, pharyngeal cancer, laryngeal cancer, lip cancer, mesothelioma, neck cancer, nasal cancer, eye cancer, ocular melanoma, pelvic cancer, rectal cancer, renal cell carcinoma, salivary gland cancer, paranasal sinus cancer, spinal cancer, tongue cancer, tubular cancer, urethral cancer, and ureteral cancer.
[0166] In some embodiments, the compounds of the present disclosure are useful for treating sickle cell disease and sickle cell anemia.
[0167] In some embodiments, diseases and indications that may be treated using the compounds of the present disclosure include, but are not limited to, hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, cancers of the nervous system, gynecological cancers, and skin cancers.
[0168] Exemplary hematological cancers include lymphomas and leukemias, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, non-Hodgkin lymphoma (including relapsed or refractory NHL and relapsed follicular NHL), Hodgkin lymphoma, myeloproliferative disorders (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET)), myelodysplastic syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), and multiple myeloma (MM).
[0169] Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdomyosarcoma, fibroma, lipoma, hamartoma, and teratoma.
[0170] Exemplary lung cancers include non-small cell lung cancer (NSCLC) (e.g., squamous cell NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchial) carcinoma, bronchial adenoma, enchondroma hamartoma, and mesothelioma.
[0171] Exemplary gastrointestinal cancers include esophageal cancer (carcinoma, squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), gastric cancer (carcinoma, lymphoma, leiomyosarcoma, adenocarcinoma), pancreatic cancer (ductal adenocarcinoma, insulinoma, pancreatic glucagonoma, gastrinoma, carcinoid tumor, vipoma), small intestine cancer (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), colorectal cancer (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal cancer (e.g., colorectal adenocarcinoma).
[0172] Exemplary genitourinary tract cancers include renal cancer (adenocarcinoma, Wilms' tumor [Nephroblastoma]), bladder and urethral cancer (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate cancer (adenocarcinoma, sarcoma), and testicular (seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatoid tumor, lipoma). In some embodiments, the cancer is a urinary tract cancer (e.g., papillary renal carcinoma, testicular germ cell carcinoma, refractory renal cell carcinoma, clear cell renal carcinoma, or prostate cancer).
[0173] Exemplary liver cancers include hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.
[0174] Exemplary bone cancers include, e.g., osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, chondroostoma (osteocartilaginous exostosis), benign enchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumor.
[0175] Exemplary cancers of the nervous system include cancers of the skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meningeal cancers (meningiomas, meningosarcomas, gliomatosis), brain cancers (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors (pinealomas), glioblastomas, glioblastomas multiforme, oligodendrocytomas, schwannomas, retinoblastomas, congenital tumors), and spinal cord cancers (neurofibromas, meningiomas, gliomas, sarcomas), as well as neuroblastoma and Lhermitte-Duclos disease.
[0176] Exemplary gynecological cancers include uterine cancer (endometrial cancer), cervical cancer (cervical carcinoma, preneoplastic cervical atypical hyperplasia), ovarian cancer (ovarian carcinoma (serous cystadenocarcinoma, serous adenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa cell-theca cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulvar cancer (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vaginal cancer (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tube cancer (carcinoma).
[0177] Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma (e.g., cutaneous squamous cell carcinoma), Kaposi's sarcoma, dysplastic nevi, lipomas, hemangiomas, dermatofibromas, and keloids. In some embodiments, diseases and indications that may be treated using the compounds of the present disclosure include, but are not limited to, sickle cell disease (e.g., sickle cell anemia), triple negative breast cancer (TNBC), myelodysplastic syndrome, testicular cancer, bile duct cancer, esophageal cancer, and urothelial cancer.
[0178] Blocking the PD-1 pathway using the compounds of the present disclosure can also be used to treat infections, such as viral, bacterial, fungal and parasitic infections. The present disclosure provides a method for treating an infection (e.g., a viral infection). The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the formulas described herein, such as a compound described in any one of the claims and described herein, and a salt thereof. Examples of viruses causing infections treatable by the methods of the present disclosure include, but are not limited to, human immunodeficiency virus, human papillomavirus, influenza virus, hepatitis A, B, C or D virus, adenovirus, poxvirus, herpes simplex virus, human cytomegalovirus, severe acute respiratory syndrome virus, ebola virus and measles virus. In some embodiments, viruses that cause infections treatable by the methods of the present disclosure include, but are not limited to, hepatitis (A, B, or C) viruses, herpes viruses (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, flavivirus, echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus, tuberculosis virus, and arboviral encephalitis virus.
[0179] The present disclosure provides a method for treating bacterial infection. The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the formulae described herein, a compound as recited in any of the claims and described herein, or a salt thereof. Non-limiting examples of pathogenic bacteria causing infections treatable by the methods of the present disclosure include chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
[0180] The present disclosure provides a method for treating fungal infection. The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the formulae described herein, a compound as recited in any of the claims and described herein, or a salt thereof. Non-limiting examples of pathogenic fungi causing infections treatable by the methods of the present disclosure include Candida (Candida albicans, Candida krusei, Candida glabrata, Candida tropicalis, etc.), Cryptococcus neoformans, Aspergillus (Aspergillus fumigatus, Aspergillus niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, and the like. immitis and Histoplasma capsulatum.
[0181] The present disclosure provides a method for treating parasitic infections, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the formulae described herein, a compound as recited in any of the claims and described herein, or a salt thereof. Non-limiting examples of pathogenic parasites causing infections treatable by the methods of the present disclosure include Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
[0182] The present disclosure provides a method for treating a neurodegenerative disease or condition. The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the formulas described herein, a compound as described in any one of the claims and as described herein, or a salt thereof. Non-limiting examples of neurodegenerative diseases or conditions include Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, motor neuron disease, spinocerebellar ataxia, and spinal muscular atrophy.
[0183] It is believed that the compounds of formula (I) or any of its embodiments may have a satisfactory pharmacological profile and promising biopharmaceutical properties, such as toxicological profiles, metabolic and pharmacokinetic properties, solubility and permeability. It will be appreciated that the determination of appropriate biopharmaceutical properties is within the knowledge of those skilled in the art, such as determining cytotoxicity in cells or inhibition of certain targets or pathways to determine potential toxicity.
[0184] The terms "subject" or "patient" are used interchangeably and refer to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, or primates, and most preferably humans.
[0185] The phrase "therapeutically effective amount" refers to that amount of an active compound or agent that elicits the biological or medical response in a tissue, system, animal, individual or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
[0186] As used herein, the terms "treating" or "treatment" refer to one or more of the following: (1) inhibiting a disease; e.g., inhibiting a disease, disorder or condition in an individual experiencing or developing the pathology or symptoms of a disease, disorder or condition (i.e., preventing the pathology and / or symptoms from developing further); and (2) ameliorating a disease; e.g., ameliorating a disease, disorder or condition in an individual experiencing or developing the pathology or symptoms of a disease, disorder or condition (i.e., reversing the pathology and / or symptoms), e.g., reducing the severity of the disease.
[0187] In some embodiments, the compounds of the invention are useful for preventing or reducing the risk of developing any of the diseases mentioned herein; for example, preventing or reducing the risk of developing a disease, disorder or condition in an individual who is susceptible to the disease, disorder or condition but has not yet experienced or developed the signs or symptoms of the disease.
[0188] Combination therapy
[0189] Cancer cell growth and survival are affected by dysfunction of multiple biological pathways. Therefore, combining inhibitors of different mechanisms, such as enzyme inhibitors, signal transduction inhibitors, inhibitors of chromatin dynamics, or immune response modifiers, can be used to treat such diseases. Targeting more than one signaling pathway (or more than one biomolecule involved in a given signaling pathway) can reduce the likelihood of drug resistance in a cell population and / or reduce treatment toxicity.
[0190] The compounds of the present disclosure can be used in combination with one or more therapies for treating diseases such as cancer or infection. Examples of diseases and indications that can be treated with combination therapy include diseases and indications as described herein. Examples of cancer include solid tumors and non-solid tumors, such as liquid tumors, blood cancers. Examples of infection include viral infection, bacterial infection, fungal infection or parasitic infection. For example, the compounds of the present disclosure can be used in combination with one or more inhibitors of the following kinases for the treatment of cancer: Akt1, Akt2, Akt3, BCL2, CDK, TGF-βR, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IDH2, IGF-1R, IR-R, PDGFαR, PDGFβR, PI3K (α, β, γ, δ and multiplicity or selectivity), CSF1R, KIT, FLK-II , KDR / FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, PARP, Ron, Sea, TRKA, TRKB, TRKC, TAM kinases (Axl, Mer, Tyro3), FLT3, VEGFR / Flt2, Flt4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. In some embodiments, the compounds of the present disclosure can be combined with one or more of the following inhibitors for the treatment of cancer or infection. Non-limiting examples of inhibitors that can be combined with the compounds of the present disclosure for the treatment of cancer and infection include FGFR inhibitors (FGFR1, FGFR2, FGFR3 or FGFR4, such as pemigatinib (INCY54828), INCB62079), JAK inhibitors (JAK1 and / or JAK2, such as ruxolitinib, baricitinib or itacitinib (INCB39110)), IDO inhibitors ( For example, epacadostat, NLG919 or BMS-986205, MK7162), LSD1 inhibitors (such as INCB59872 and INCB60003), TDO inhibitors, PI3K-δ inhibitors (such as Parsaclisib (INCB50465) and INCB50797), PI3K-γ inhibitors (such as PI3K-γ selective inhibitors), Pim inhibitors (such as INCB53914), EGFR inhibitors (also known as ErB-1 or HER-1;(eg, erlotinib, gefitinib, vandetanib, orsimertinib, cetuximab, necitumumab, or panitumumab), VEGFR inhibitors or pathway blockers (eg, bevacizumab, pazopanib, sunitinib, sorafenib, axitinib, itinib, regorafenib, ponatinib, cabozantinib, axitinib, vandetanib, ramucirumab, lenvatinib, ziv-aflibercept), PARP inhibitors (such as olaparib, rucaparib, veliparib, talazoparib, or niraparib) ib)), CSF1R inhibitors, TAM receptor tyrosine kinases (Tyro-3, Axl and Mer), adenosine nucleoside receptor antagonists (e.g., A2a / A2b receptor antagonists), HPK1 inhibitors, chemokine receptor inhibitors (e.g., CCR2 or CCR5 inhibitors), SHP1 / 2 phosphatase inhibitors, histone deacetylase inhibitors (HDAC) (e.g., HDAC8 inhibitors), angiogenesis inhibitors, interleukin receptor inhibitors, bromodomain and extra-terminal domain family member inhibitors (e.g., bromodomain inhibitors or BET inhibitors, such as INCB5432 9 and INCB57643), arginase inhibitors (INCB001158), PARP inhibitors (e.g., rucaparib or olaparib), sitravatinib, B-Raf inhibitor-MEK inhibitor combinations (e.g., encorafenib plus binimetinib, dabrafenib plus trametinib or cobimetinib plus vemurafenib), and adenosine nucleoside receptor antagonists or combinations thereof. ;
[0191] In some embodiments, compounds of the present disclosure may be combined with a TLR7 agonist (eg, imiquimod).
[0192] The compounds disclosed herein can also be used in combination with other cancer treatment methods, such as chemotherapy, radiotherapy, tumor-targeted therapy, adjuvant therapy, immunotherapy or surgery. Examples of immunotherapy include cytokine therapy (e.g., interferon, GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccines, monoclonal antibodies, bispecific or multispecific antibodies, antibody drug conjugates, adoptive T cell transfer, Toll receptor agonists, STING agonists, RIG-I agonists, oncolytic virus therapy and immunomodulatory small molecules, including thalidomide or JAK1 / 2 inhibitors, PI3Kδ inhibitors, etc. The compound can be administered in combination with one or more anticancer drugs, such as chemotherapeutic agents. Examples of chemotherapeutic agents include any of the following: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin, bortezomib, intravenous busulfan, intravenous, oral busulfanoral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, actinomycin D, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin-diphtheria toxin conjugate diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionatepropionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab tuzumab, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate mesylate, interferon α2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetateacetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolonephenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexeddisodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, nacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, and zoledronate.
[0193] Other anticancer agents include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4 (e.g., ipilimumab), 4-1BB (e.g., urelumab, utomilumab), antibodies to PD-1 and PD-L1, or antibodies to cytokines (IL-10, TGF-β, etc.). Examples of antibodies to PD-1 and / or PD-L1 that can be used in combination with the compounds of the present disclosure for the treatment of cancer or infections such as viral, bacterial, fungal, and parasitic infections include, but are not limited to, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, and SHR-1210.
[0194] The compounds disclosed herein can be used in combination with one or more immune checkpoint inhibitors for treating diseases such as cancer or infection. Exemplary immune checkpoint inhibitors include inhibitors for, for example, the following immune checkpoint molecules: CBL-B, CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3Kδ, PI3Kγ, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, TIGIT, CD112R, VISTA, PD-1, PD-L1 and PD-L2. In some embodiments, immune checkpoint molecules are stimulatory checkpoint molecules selected from CD27, CD28, CD40, ICOS, OX40, GITR and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3 and VISTA. In some embodiments, the compound provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 284 inhibitors and TGFRβ inhibitors.
[0195] In some embodiments, the inhibitor of an immune checkpoint molecule is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
[0196] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-1, such as an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD1 antibody is pembrolizumab.
[0197] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-L1, such as an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A or MEDI4736.
[0198] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CTLA-4, such as an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab or tremelimumab.
[0199] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of LAG3, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016, LAG525 or INCAGN2385.
[0200] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of TIM3, such as an anti-TIM3 antibody. In some embodiments, the anti-TIM3 antibody is INCAGN2390, MBG453 or TSR-022.
[0201] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of GITR, such as an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323 or MEDI1873.
[0202] In some embodiments, the inhibitor of the immune checkpoint molecule is an OX40 inhibitor, such as an anti-OX40 antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, or BMS-986178. In some embodiments, the OX40L fusion protein is MEDI6383.
[0203] The compounds of the invention may also be used in combination with one or more anti-inflammatory agents, steroids, immunosuppressants or therapeutic antibodies.
[0204] The compound of formula (I) or any of the formulas as described herein, the compound as recited in any one of the claims and as described herein, or a salt thereof, can be combined with another immunogenic agent, such as cancer cells, purified tumor antigens (including recombinant proteins, peptides and carbohydrate molecules), cells, and cells transfected with genes encoding immunostimulatory cytokines. Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as gp100, MAGE antigens, Trp-2, MARTI and / or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.
[0205] Compounds of formula (I) or any of the formulas as described herein, compounds as described in any of the claims and described herein, or salts thereof, can be used in combination with vaccination regimens for the treatment of cancer. In some embodiments, tumor cells are transduced to express GM-CSF. In some embodiments, tumor vaccines include proteins from viruses associated with human cancers, such as human papillomavirus (HPV), hepatitis viruses (HBV and HCV), and Kaposi's herpes sarcoma virus (KHSV). In some embodiments, compounds of the present disclosure can be used in combination with tumor-specific antigens such as heat shock proteins isolated from tumor tissue itself. In some embodiments, compounds of formula (I) or any of the formulas as described herein, compounds as described in any of the claims and described herein, or salts thereof, can be used in combination with dendritic cell immunizations that activate effective anti-tumor responses.
[0206] The compounds of the present disclosure may be used in combination with bispecific macrocyclic peptides that target effector cells expressing Fcα or Fcγ receptors to tumor cells. The compounds of the present disclosure may also be combined with macrocyclic peptides that activate the host immune response.
[0207] The compounds of the present disclosure can be used in combination with bone marrow transplantation to treat a variety of tumors of hematopoietic origin.
[0208] Compounds of formula (I) or any of the formulae as described herein, compounds as recited in any of the claims and as described herein, or salts thereof, may be used in combination with vaccines that stimulate immune responses to pathogens, toxins, and self-antigens. Examples of pathogens for which this treatment method is particularly useful include pathogens for which there are currently no effective vaccines or pathogens for which conventional vaccines are not fully effective. These pathogens include (but are not limited to) HIV pathogens, hepatitis (A, B, and C) pathogens, influenza pathogens, herpes pathogens, Giardia, malaria pathogens, Leishmania, Staphylococcus aureus, Pseudomonas Aeruginosa.
[0209] Viruses that cause infections treatable by the methods of the present disclosure include, but are not limited to, human papillomavirus, influenza virus, hepatitis A, B, C, or D virus, adenovirus, poxvirus, herpes simplex virus, human cytomegalovirus, severe acute respiratory syndrome virus, Ebola virus, measles virus, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein-Barr virus), flavivirus, echovirus, rhinovirus, coxsackievirus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus, and arboviral encephalitis virus.
[0210] Pathogenic bacteria causing infections treatable by the methods of the present disclosure include, but are not limited to, Chlamydia, Rickettsia, Mycobacterium, Staphylococcus, Streptococcus, Pneumococcus, Meningococcus and Gonorrhea, Klebsiella, Proteus, Serratia, Pseudomonas, Legionella, Diphtheria, Salmonella, Bacillus, Cholera, Tetanus, Botulinum, Anthrax, Plague, Leptospira, and Lyme disease bacteria.
[0211] Pathogenic fungi causing infections treatable by the methods of the present disclosure include, but are not limited to, Candida species (Candida albicans, Candida krusei, Candida glabrata, Candida tropicalis, etc.), Cryptococcus neoformans, Aspergillus species (Aspergillus fumigatus, Aspergillus niger, etc.), Mucorales (Mucor, Absidia, Rhizopus), Sporothrix schenckii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, and Histoplasma capsulatum.
[0212] Pathogenic parasites that cause infections treatable with the methods of the present disclosure include, but are not limited to, Entamoeba dysenteriae, Balantidium coli, Naegleria fowleri, Acanthamoeba, Giardia lamblia, Cryptosporidium, Pneumocystis pneumoniae, Plasmodium vivax, Babesia fruitii, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Ancylostoma brasiliensis.
[0213] When more than one agent is administered to a patient, the agents may be administered simultaneously, separately, sequentially, or in combination (eg, for more than two agents).
[0214] IV. Formulation, Dosage Formulation and Administration
[0215] When used as a drug, the compounds of the present disclosure can be administered in the form of a pharmaceutical composition. Therefore, the present disclosure provides a composition comprising a compound of formula (I) or any formula as described herein, a compound described in any one of the claims and described herein, or a pharmaceutically acceptable salt thereof, or any embodiment thereof, and at least one pharmaceutically acceptable carrier or excipient. These compositions can be prepared in a manner well known in the pharmaceutical field, and can be administered by a variety of routes, depending on whether local or systemic treatment is indicated and the area to be treated. Administration can be topical (including transdermal, epidermal, ocular and mucosal, including intranasal, vaginal and rectal delivery), pulmonary administration (e.g., by inhalation or blowing into powder or aerosol, including by a nebulizer; intratracheal or intranasal), oral administration or parenteral administration. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular administration or injection or infusion; or intracranial, such as intrathecal or intraventricular administration. Parenteral administration can be in the form of a single bolus dose, or can be, for example, by a continuous infusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
[0216] The present invention also includes pharmaceutical compositions containing a compound of the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient, and one or more pharmaceutically acceptable carriers or excipients. In some embodiments, the composition is suitable for topical administration. When manufacturing the composition of the present invention, the active ingredient is usually mixed with an excipient, diluted with an excipient, or loaded into such a carrier, in the form of, for example, a capsule, a sachet, a paper or other container. When an excipient acts as a diluent, it may be a solid, semisolid or liquid substance, acting as a vehicle, carrier or medium for the active ingredient. Therefore, the composition may be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (in solid form or in a liquid medium), ointments (containing, for example, up to 10% by weight of active compounds), soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
[0217] When preparing a formulation, the active compound may be ground before combining with the other ingredients to provide an appropriate particle size. If the active compound is substantially insoluble, it may be ground to a particle size of less than 200 mesh. If the active compound is substantially soluble in water, the particle size may be adjusted by grinding to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
[0218] The compounds of the invention may be milled using known milling procedures, such as wet milling, to obtain particle sizes suitable for tablet formation and other formulation types. Fine powder (nanoparticulate) formulations of the compounds of the invention may be prepared by methods known in the art, see for example WO2002 / 000196.
[0219] Some examples of suitable excipients include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose. The formulation may additionally include: lubricants, such as talc, magnesium stearate and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives, such as methylparaben and propylparaben; sweeteners; and flavoring agents. By adopting procedures known in the art, the compositions of the present invention can be formulated to release the active ingredient quickly, continuously or delayed after administration to the patient.
[0220] In some embodiments, the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the silicified microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w / w.
[0221] In some embodiments, the composition is a sustained release composition comprising at least one compound described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier or excipient. In some embodiments, the composition comprises at least one compound described herein or a pharmaceutically acceptable salt thereof and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide. In some embodiments, the composition comprises at least one compound described herein or a pharmaceutically acceptable salt thereof and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose. In some embodiments, the composition comprises at least one compound described herein or a pharmaceutically acceptable salt thereof and microcrystalline cellulose, lactose monohydrate and polyethylene oxide. In some embodiments, the composition further comprises magnesium stearate or silicon dioxide. In some embodiments, microcrystalline cellulose is Avicel PH102 TM In some embodiments, the lactose monohydrate is Fast-flo 316 TM In some embodiments, the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208K4M (e.g., Methocel K4 M Premier TM ) and / or hydroxypropyl methylcellulose 2208K100LV (e.g. Methocel K00LV TM In some embodiments, the polyethylene oxide is polyethylene oxide WSR 1105 (e.g., PolyoxWSR 1105 TM ).
[0222] In some embodiments, the composition is produced using a wet granulation process. In some embodiments, the composition is produced using a dry granulation process.
[0223] The composition can be formulated in unit dosage form, each dose containing about 5 to about 1,000 mg (1 g), more typically about 100 mg to about 500 mg of active ingredient. In some embodiments, each dose contains about 10 mg of active ingredient. In some embodiments, each dose contains about 50 mg of active ingredient. In some embodiments, each dose contains about 25 mg of active ingredient. The term "unit dosage form" refers to a physically discrete unit suitable for use in a single dose for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to produce the desired therapeutic effect and a suitable pharmaceutical excipient.
[0224] The components used to formulate the pharmaceutical composition are of high purity and substantially free of potentially harmful contaminants (e.g., at least national food grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Especially for human consumption, the composition is preferably manufactured or formulated according to good manufacturing practice standards as defined in applicable regulations of the US Food and Drug Administration. For example, suitable formulations may be sterile, and / or substantially isotonic, and / or fully comply with all good manufacturing practice regulations of the US Food and Drug Administration.
[0225] The active compound can be effective over a wide dosage range and is generally administered in a therapeutically effective amount. However, it should be understood that the amount of compound actually administered will generally be determined by the physician based on relevant circumstances, including the condition to be treated, the selected route of administration, the actual compound administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, etc.
[0226] The therapeutic dose of the compounds of the present invention can be varied according to, for example, specific therapeutic use, the mode of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compounds of the present invention in the pharmaceutical composition can vary depending on many factors including dosage, chemical properties (e.g., hydrophobicity), and route of administration. For example, the compounds of the present invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w / v of the compound for parenteral administration. Some typical dosage ranges are about 1 μg to about 1 g per kilogram of body weight per day. In some embodiments, the dosage range is about 0.01 mg to about 100 mg per kilogram of body weight per day. The dosage is likely to depend on, for example, the type and degree of progression of the disease or condition, the overall health status of the specific patient, the relative biological efficacy of the selected compound, the formulation of the excipient, and the variables of its route of administration. The effective dose can be extrapolated from a dose-response curve derived from an in vitro or animal model test system.
[0227] In order to prepare a solid composition such as a tablet, the main active ingredient is mixed with a pharmaceutical excipient to form a solid preformulated composition containing a uniform mixture of the compound of the invention. When these preformulated compositions are referred to as homogeneous, the active ingredient is generally evenly dispersed in the composition so that the composition is easily subdivided into equally effective unit dosage forms, such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the above type containing, for example, about 0.1 mg to about 1000 mg of the active ingredient of the invention.
[0228] Tablets or pills of the present invention can be coated with coatings or otherwise compounded to obtain dosage forms that provide benefits of long-term effects. For example, tablets or pills can include internal and external dispensing components, the latter being in the form of a film coating on the former. The two components can be separated by an enteric coating layer that is used to resist disintegration in the stomach and allows the internal component to enter the duodenum intact or delay release. Various materials can be used for such enteric coating layers or coatings, including a large amount of polyacids and polyacids with, for example, shellac, cetyl alcohol, and cellulose acetate.
[0229] Liquid forms in which the compounds and compositions of the invention may be incorporated for oral or injection administration include aqueous solutions, appropriately flavored syrups, aqueous or oily suspensions and flavored emulsions containing edible oils (e.g., cottonseed oil, sesame oil, coconut oil, or peanut oil), as well as elixirs and similar pharmaceutical vehicles.
[0230] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, and powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. In some embodiments, the composition is administered by oral or nasal respiratory route to achieve local or systemic effects. The composition may be atomized by the use of an inert gas. The atomized solution may be breathed directly from a spray device, or the atomizing device may be connected to a mask, tent, or intermittent positive pressure breathing machine. Solutions, suspensions, or powder compositions may be administered orally or nasally from a device that delivers the formulation in an appropriate manner.
[0231] The topical preparation can contain one or more conventional carriers. In some embodiments, the ointment can contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white vaseline, etc. The carrier composition of the cream can be based on water and glycerol and one or more other components (such as glyceryl monostearate, PEG-glyceryl monostearate and cetearyl alcohol) combination. Gels can use isopropyl alcohol and water, suitably formulated with other components such as glycerol, hydroxyethyl cellulose, etc. In some embodiments, the topical preparation contains at least about 0.1% by weight, at least about 0.25% by weight, at least about 0.5% by weight, at least about 1% by weight, at least about 2% by weight or at least about 5% by weight of the compounds of the present invention. The topical preparation is preferably, for example, packaged in a tube with 100g, and the tube is optionally associated with instructions for the selected indications for treating, for example, psoriasis or other skin disorders.
[0232] The amount of compound or composition administered to a patient will vary depending on the article being administered, the purpose of administration (e.g., prevention or treatment), the patient's state, the mode of administration, and the like. In therapeutic applications, the composition can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially prevent the symptoms of the disease and its complications. The effective dose will depend on the disease condition being treated and will be determined by the attending physician depending on factors such as the severity of the disease, the patient's age, weight, and overall condition, and the like.
[0233] The composition administered to the patient can be in the form of the above-mentioned pharmaceutical composition. These compositions can be sterilized by conventional sterilization techniques, or can be aseptically filtered. The aqueous solution can be packaged for use as is, or lyophilized, and the lyophilized preparation is combined with a sterile aqueous carrier before administration. The pH value of the compound preparation will generally be between 3 and 11, more preferably 5 to 9 and most preferably 7 to 8. It should be understood that the use of some of the above-mentioned excipients, carriers or stabilizers will form a pharmaceutical salt.
[0234] The therapeutic dose of the compounds of the present invention may vary according to, for example, specific therapeutic uses, the mode of administration of the compounds, the health and condition of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compounds of the present invention in the pharmaceutical composition may vary depending on many factors including dosage, chemical properties (e.g., hydrophobicity), and route of administration. For example, the compounds of the present invention may be provided in an aqueous physiological buffer solution containing about 0.1% w / v to about 10% w / v of the compound for parenteral administration. Some typical dosage ranges are about 1 μg to about 1 g per kilogram of body weight per day. In some embodiments, the dosage range is about 0.01 mg to about 100 mg per kilogram of body weight per day. The dosage is likely to depend on, for example, the type and degree of progression of the disease or condition, the overall health status of the specific patient, the relative biological efficacy of the selected compound, the formulation of the excipient, and the variables of its route of administration. The effective dose can be extrapolated from a dose-response curve derived from an in vitro or animal model test system.
[0235] V. Labeled Compounds and Assay Methods
[0236] The compounds disclosed herein can also be used to study biological processes in normal and abnormal tissues. Therefore, another aspect of the present invention relates to the labeled compounds of the present invention (radioactive labels, fluorescent labels, etc.), which can be used not only in imaging techniques, but also in in vitro and in vivo assays for locating and quantifying PD-1 or PD-L1 proteins in tissue samples including humans, and identifying PD-L1 ligands by inhibiting the binding of labeled compounds. Therefore, the present invention includes PD-1 / PD-L1 binding assays containing such labeled compounds.
[0237] The present invention also includes isotopically substituted compounds of the present disclosure. An "isotopically substituted" compound is a compound of the present invention in which one or more atoms are replaced or substituted by atoms having the same atomic number but a different atomic mass or mass number, e.g., an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). It should be understood that a "radiolabeled" compound is a compound into which at least one radioactive isotope (e.g., a radionuclide) is incorporated. Suitable radionuclides that can be incorporated into the compounds of the present invention include, but are not limited to 3 H (tritium is also written as T), 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 18 F. 35 S. 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 I. 124 I. 125 I and 131 I. The radionuclide incorporated into the radiolabeled compounds of the invention will depend on the specific application of the radiolabeled compound. For example, for in vitro PD-L1 protein labeling and competition assays, incorporation of 3 H. 14 C. 82 Br, 125 I. 131 I. 35 For radioactive imaging applications, 11 C. 18 F. 125 I. 123 I. 124 I. 131 I. 75 Br, 76 Br or 77 Br is generally the most useful.
[0238] In some embodiments, the radionuclide is selected from 3 H. 14 C. 125 I. 35 S and 82 Synthetic methods for incorporating radioisotopes into organic compounds are known in the art.
[0239] Specifically, the labeled compounds of the present invention can be used in screening assays to identify and / or evaluate compounds. For example, the ability of a newly synthesized or identified labeled compound (i.e., a test compound) to bind to the PD-L1 protein can be evaluated by tracking the label and monitoring the concentration change when in contact with the PD-L1 protein. For example, the ability of the test compound (label) to reduce the binding of another compound (i.e., a standard compound) known to bind to the PD-L1 protein can be evaluated. Therefore, the ability of the test compound to compete with the standard compound for binding to the PD-L1 protein is directly related to its binding affinity. In contrast, in some other screening assays, the standard compound is labeled and the test compound is not labeled. Therefore, the concentration of the labeled standard compound is monitored to evaluate the competition between the standard compound and the test compound, and thus determine the relative binding affinity of the test compound.
[0240] VI.Medicine Box
[0241] The present disclosure also includes kits that can be used, for example, to treat or prevent diseases or conditions associated with PD-L1 activity, including interactions of PD-L1 with other proteins, such as PD-1 and B7-1 (CD80), such as cancer or infection, comprising one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or any embodiment thereof. Such kits may also include one or more of a variety of conventional kit components, such as containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be apparent to those skilled in the art. The kit may also include instructions as inserts or as labels indicating the dosage of the components, application guidelines, and / or component mixing guidelines.
[0242] The following abbreviations may be used herein: aq. (aqueous solution); br (broad); d (doublet); dd (doublet); DCM (dichloromethane); DMF (N,N-dimethylformamide); Et (ethyl); EtOAc (ethyl acetate); g (gram); h (hour); HPLC (high performance liquid chromatography); Hz (hertz); J (coupling constant); LCMS (liquid chromatography-mass spectrometry); m (multiplet); M (molarity); MS (mass spectrometry); Me (methyl); MeCN (ethyl); nitrile); MeOH (methanol); mg (milligram); min. (minute); mL (milliliter); mmol (millimole); nM (nanomolar); NMR (nuclear magnetic resonance spectroscopy); Ph (phenyl); rt (room temperature), s (singlet); t (triplet or tert-butyl); TBS (tert-butyldimethylsilyl); tert (tert-butyldimethylsilyl); tt (triplet of triplet); TFA (trifluoroacetic acid); THF (tetrahydrofuran); μg (microgram); μL (microliter); μM (micromolar); wt% (weight percent).
[0243] The present invention will be described in more detail by specific examples. The following examples are provided for illustrative purposes and are not intended to limit the present invention in any way. One skilled in the art will readily recognize a number of non-critical parameters that can be varied or modified with substantially the same results. The compounds of the examples have been found to inhibit the activity of PD-1 / PD-L1 protein / protein interactions according to at least one assay described herein.
[0244] Example
[0245] The experimental procedures for the compounds of the present invention are provided below. On a Waters mass-guided fractionation system, some of the prepared compounds were subjected to open access preparative LCMS purification. The basic equipment settings, protocols and control software for operating these systems have been described in detail in the literature. See, for example, Blom, "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 2002, 4, 295-301; Blom et al., "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. Combi. Chem., 2003, 5, 670-83; and Blom et al., "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. Combi. Chem., 2004, 6, 874-883.
[0246] Example 1
[0247] (R)-1-((7-cyano-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0248]
[0249] Step 1: Methyl 3-chloro-4-hydroxy-5-nitrobenzoate
[0250]
[0251] To a solution of methyl 3-chloro-4-hydroxybenzoate (Alfa Aesar, #A512389: 10.0 g, 53.6 mmol) in acetic acid (20.0 mL) was added a mixture of acetic acid (20.0 mL) and nitric acid (4.72 mL, 112 mmol) dropwise at 0°C. The ice bath was then removed and the thick mixture was stirred at room temperature for 2 hours. An equal volume of water was then added to the reaction suspension at 0°C. The mixture was filtered and washed with cold water. A yellow solid was obtained as the desired product without further purification. LC-MSC8H7ClNO5(M+H) + Calculated value: m / z = 232.0; found value 232.0.
[0252] Step 2: 3-Amino-5-chloro-4-hydroxybenzoic acid methyl ester
[0253]
[0254] Methyl 3-chloro-4-hydroxy-5-nitrobenzoate (2.08 g, 8.98 mmol) was hydrogenated under ambient pressure of hydrogen using palladium / carbon (10 wt%, 0.57 g, 0.539 mmol) in ethyl acetate (15 mL) for 1 hour. The resulting suspension was filtered through a Celite pad and washed with EtOAc and the solvent was removed under reduced pressure to give the crude product which was purified by column chromatography (eluting with MeOH / DCM 0%-10%). LC-MS C8H9ClNO3 (M+H) + Calculated value: m / z = 202.0; found value 202.0.
[0255] Step 3: Methyl 2-(3-bromo-2-methylphenyl)-7-chlorobenzo[d]oxazole-5-carboxylate
[0256]
[0257] A mixture of methyl 3-amino-5-chloro-4-hydroxybenzoate (1.04 g, 5.16 mmol), 3-bromo-2-methylbenzaldehyde (AstaTech, #52940: 0.98 g, 4.92 mmol) in EtOH (25 ml) was placed in a vial and stirred at room temperature for 1 hour. The mixture was then concentrated. The residue was redissolved in dichloromethane (25 mL) and dichlorodicyanoquinone (1.12 g, 4.92 mmol) was added. The mixture was stirred at room temperature for 30 minutes. The reactants were diluted with dichloromethane and washed with aqueous Na2S2O3 and NaHCO3 solutions. The organic phase was dried over MgSO4, filtered and the filtrate was concentrated. The crude residue was used directly without further purification. LC-MS C 16 H 12 BrClNO3(M+H)+ Calculated value: m / z = 380.0; found value 379.9.
[0258] Step 4: (2-(3-Bromo-2-methylphenyl)-7-chlorobenzo[d]oxazol-5-yl)methanol
[0259]
[0260] To a solution of methyl 2-(3-bromo-2-methylphenyl)-7-chlorobenzo[d]oxazole-5-carboxylate (395.0 mg, 1.04 mmol) in DCM (10.0 ml) was added dropwise a DCM solution of diisobutylaluminum hydride (1.0 M, 2.08 ml, 2.08 mmol) at -78 °C. The mixture was slowly warmed to 0 °C. The mixture was then quenched with EtOAc and DCM, followed by an aqueous solution of Rochell's salt. The mixture was stirred vigorously at room temperature for 1 hour. The organic phase was separated and dried over MgSO4, then filtered through a short Celite pad to remove solids. The filtrate was concentrated and purified by column chromatography (eluted with 0-5% MeOH / DCM). LC-MS C 15 H 12 BrClNO2(M+H) + Calculated value: m / z = 352.0; found value 352.0.
[0261] Step 5: (7-Chloro-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazol-5-yl)methanol
[0262]
[0263] A mixture of (2-(3-bromo-2-methylphenyl)-7-chlorobenzo[d]oxazol-5-yl)methanol (113 mg, 0.322 mmol), bis(pinacolato)diboron (98 mg, 0.386 mmol), dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (26.3 mg, 0.032 mmol) and anhydrous potassium acetate (79 mg, 0.804 mmol) in 1,4-dioxane (3.5 mL) was purged with nitrogen and stirred at 110° C. for 2 hours. The crude material was diluted with DCM and then filtered through Celite. The filtrate was concentrated. The residue was purified by flash chromatography eluting with 0-40% EtOAc / hexanes. LC-MS C 21 H 24 BClNO4(M+H) + Calculated value: m / z = 400.2; found value 400.2.
[0264] Step 6: 5-(Hydroxymethyl)-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazole-7-carbonitrile
[0265]
[0266] A stirred mixture of (7-chloro-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazol-5-yl)methanol (1.08 g, 2.63 mmol), zinc cyanide (0.253 g, 2.11 mmol) and methanesulfonate (2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl) (2′-amino-1,1′-biphenyl-2-yl) palladium (II) (0.171 g, 0.211 mmol) in THF (5.27 ml) and water (5.27 ml) was degassed and backfilled three times with N2 at room temperature. It was heated at 90° C. overnight. The reaction mixture was diluted with THF while hot. It was cooled to room temperature and filtered to remove insoluble solids. The filtrate was concentrated in vacuo. Acetonitrile was then added. The resulting slurry was filtered and washed with acetonitrile. The solid was collected and used directly in the next step without further purification. LC-MS C 22 H 24 BN2O4(M+H) + Calculated value: m / z = 391.2; Found: 391.2.
[0267] Step 7: 5-Formyl-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazole-7-carbonitrile
[0268]
[0269] To a solution of 5-(hydroxymethyl)-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazole-7-carbonitrile (1.51 g, 3.68 mmol) in DCM (16.4 mL) and DMF (2.0 ml) was added Dess-Martin periodinane (2.49 g, 5.70 mmol). The mixture was stirred at room temperature for 3 hours. The crude mixture was quenched with saturated Na2S2O3 and saturated NaHCO3. The mixture was extracted three times with DCM. The organic phases were combined, dried and filtered. The filtrate was concentrated. Diethyl ether was added to the residue to form a slurry, which was filtered to give the desired aldehyde. LCMS C22 H 22 Calculated value for BN2O4(M+H)+: m / z=389.2; Found 389.2.
[0270] Step 8: 7-Bromo-N-(3-chloro-2-methylphenyl)-2-methylpyrido[3,2-d]pyrimidin-4-amine
[0271]
[0272] To a mixture of 7-bromo-2-methylpyrido[3,2-d]pyrimidin-4-ol (Combi-Blocks, catalog number ST-6117: 175 mg, 0.729 mmol), benzyltriethylammonium chloride (332 mg, 1.46 mmol) and N,N-diethylaniline (174 μl, 1.09 mmol) in acetonitrile (3.6 ml) was added phosphorus oxychloride (408 μl, 4.37 mmol). The mixture was stirred at 90° C. for 2 hours. The reaction was then cooled to room temperature. Volatiles were removed under reduced pressure. The residue was used directly.
[0273] 3-Chloro-2-methylaniline (113 mg, 0.800 mmol) and methanesulfonic acid (47.2 μl, 0.727 mmol) were added to 2-propanol (3.6 ml) containing the above residue. The mixture was stirred at 80°C for 2 hours. The reaction was then cooled to room temperature. The mixture was carefully quenched by aqueous NaHCO3 solution and extracted with DCM. The combined DCM solution was dried over MgSO4 and filtered. The filtrate was concentrated. The residue was purified by flash chromatography (0-70% EtOAc / hexane). LC-MS C 15 H 13 BrClN4(M+H) + Calculated value: m / z = 363.0; found value 363.0.
[0274] Step 9: N-(3-chloro-2-methylphenyl)-2-methyl-7-vinylpyrido[3,2-d]pyrimidin-4-amine
[0275]
[0276] A mixture of 7-bromo-N-(3-chloro-2-methylphenyl)-2-methylpyrido[3,2-d]pyrimidin-4-amine (250 mg, 0.687 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (159 mg, 1.03 mmol), tetrakis(triphenylphosphine)palladium(0) (79 mg, 0.069 mmol) and potassium phosphate (365 mg, 1.72 mmol) in tert-butyl alcohol (3.4 ml) and water (3.4 ml) was purged with N2 and sealed. The resulting mixture was stirred at 100°C for 3 hours. The reaction mixture was cooled and then extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was used directly in the next step without further purification. LC-MS C 17 H 16 ClN4(M+H) + Calculated value: m / z = 311.2; Found 311.2.
[0277] Step 10: 4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidine-7-carbaldehyde
[0278]
[0279] A vial was charged with N-(3-chloro-2-methylphenyl)-2-methyl-7-vinylpyrido[3,2-d]pyrimidin-4-amine (214 mg, 0.689 mmol), THF (5.5 ml), a stirring bar and water (1.4 ml). To this solution was added sodium periodate (736 mg, 3.44 mmol) followed by osmium tetroxide (4% w / w in water, 270 μl, 0.034 mmol). After stirring at room temperature for 1 hour, the reaction was quenched with saturated aqueous sodium thiosulfate. The mixture was then extracted with DCM and the combined organic layers were washed with water, brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude residue was used directly in the next step without further purification. LC-MS C 16 H 14 Calculated value for ClN4O(M+H)+: m / z=313.1; found value 313.1.
[0280] Step 11: (R)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methyl)pyrrolidin-3-ol
[0281]
[0282] A mixture of 4-((3-chloro-2-methylphenyl)amino)-2-methylpyrido[3,2-d]pyrimidine-7-carbaldehyde (215 mg, 0.687 mmol) and (R)-pyrrolidin-3-ol (71.9 mg, 0.825 mmol) in DCM (4.6 ml) was stirred at room temperature for 30 minutes. Sodium triacetoxyborohydride (219 mg, 1.03 mmol) was then added. The mixture was further stirred at room temperature for 1 hour. The reaction was quenched with NH4OH aqueous solution and extracted with DCM. The organic phases were combined and dried over MgSO4. After filtration, the DCM solution was concentrated and the residue was purified by flash chromatography (0-12% MeOH / DCM) to give the desired product. LC-MS C 20 H 23 ClN5O(M+H) + Calculated value: m / z = 384.2; Found 384.2.
[0283] Step 12: (R)-5-Formyl-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile
[0284]
[0285] (R)-1-((4-((3-chloro-2-methylphenyl)amino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methyl)pyrrolidin-3-ol (229 mg, 0.597 mmol), 5-formyl-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazole-7-carbonitrile (Step 7: 255 mM) were added. A mixture of 2-(4-(2 ... 36 H 32 N7O3(M+H) + Calculated value: m / z = 610.3; found value 610.4.
[0286] Step 13: (R)-1-((7-cyano-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0287] A mixture of (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile (16 mg, 0.026 mmol) and tert-butyl piperidine-4-carboxylate (9.7 mg, 0.052 mmol) in DCM (500 μL) was stirred at room temperature for 2 hours. Sodium triacetoxyborohydride (16.7 mg, 0.079 mmol) was then added. The mixture was further stirred at room temperature for 1 hour. The reaction was treated with trifluoroacetic acid (404 μL, 5.25 mmol) and stirred at room temperature for 30 minutes. After evaporation of the volatiles, the residue was diluted in MeOH and purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired TFA salt. LC-MS C 42 H 43 N8O4(M+H) + Calculated value: m / z = 723.3; Found: 723.3. 1 H NMR (500MHz, DMSO) δ9.08 (s, 1H), 8.38 (d, J = 9.5Hz, 2H), 8.19 (d, J = 7.1Hz, 1H), 8.10 (s, 1H), 7. 65-7.55 (m, 2H), 7.48 (d, J=6.8Hz, 1H), 7.42 (t, J=7.7Hz, 1H), 7.18 (d, J=7.5Hz, 1H), 4.72 (s, 2 H), 4.59-4.41(m, 3H), 3.76-3.20(m, 6H), 3.09-2.90(m, 2H), 2.56(s, 3H), 2.49(s, 3H), 2.48(s , 1H), 2.39-2.25(m, 1H), 2.14-2.02(m, 2H), 1.96(s, 3H), 1.96-1.86(m, 1H), 1.80-1.68(m, 2H).
[0288] Example 2
[0289] (R)-1-((7-cyano-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0290]
[0291] Step 1: (R)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methyl)-3-methylpyrrolidin-3-ol
[0292]
[0293] This compound was prepared using a procedure similar to that described for Example 1, Step 11, substituting (R)-3-methylpyrrolidin-3-ol for (R)-pyrrolidin-3-ol. LC-MS C 21 H 25 ClN5O(M+H) + Calculated value: m / z = 398.2; Found 398.2.
[0294] Step 2: (R)-5-Formyl-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile
[0295]
[0296] This compound was prepared using a procedure analogous to that described for Example 1, Step 12, substituting (R)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methyl)-3-methylpyrrolidin-3-ol (Step 1) for (R)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methyl)pyrrolidin-3-ol. LC-MS C 37 H 34 N7O3(M+H) + Calculated value: m / z = 624.3; Found 624.3.
[0297] Step 3: (R)-1-((7-cyano-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0298] This compound was prepared using a procedure similar to that described for Example 1, Step 13, replacing (R)-5-formyl-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Step 2). The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 43 H 45 N8O4(M+H) + Calculated value: m / z = 737.4; Found: 737.4.
[0299] Example 3
[0300] (S)-1-((7-cyano-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0301]
[0302] Step 1: (S)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methyl)-3-methylpyrrolidin-3-ol
[0303]
[0304] This compound was prepared using a procedure similar to that described for Example 1, Step 11, substituting (S)-3-methylpyrrolidin-3-ol for (R)-pyrrolidin-3-ol. LC-MS C 21 H 25 ClN5O(M+H) + Calculated value: m / z = 398.2; Found 398.2.
[0305] Step 2: (S)-5-Formyl-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile
[0306]
[0307] This compound was prepared using a procedure analogous to that described for Example 1, Step 12, substituting (S)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methyl)-3-methylpyrrolidin-3-ol (Step 1) for (R)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methyl)pyrrolidin-3-ol. LC-MSC 37 H 34 N7O3(M+H) + Calculated value: m / z = 624.3; Found 624.3.
[0308] Step 3: (S)-1-((7-cyano-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0309] This compound was prepared using a procedure similar to that described for Example 1, Step 13, replacing (R)-5-formyl-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Step 2). The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 43 H 45 N8O4(M+H) + Calculated value: m / z = 737.4; Found: 737.4.
[0310] Example 4
[0311] (S)-1-((7-cyano-2-(3′-(7-((1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0312]
[0313] Step 1: (S)-2-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methylamino)propan-1-ol
[0314]
[0315] This compound was prepared using a procedure similar to that described for Example 1, Step 11, substituting (S)-2-aminopropan-1-ol for (R)-pyrrolidin-3-ol. LC-MS C 19 H 23 ClN5O(M+H) + Calculated value: m / z = 372.2; Found 372.2.
[0316] Step 2: (S)-5-Formyl-2-(3′-(7-((1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile
[0317]
[0318] This compound was prepared using a procedure analogous to that described for Example 1, Step 12, substituting (S)-2-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methylamino)propan-1-ol (Step 1) for (R)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methyl)pyrrolidin-3-ol. LC-MS C 35 H 32 N7O3(M+H) + Calculated value: m / z = 598.3; Found 598.3.
[0319] Step 3: (S)-1-((7-cyano-2-(3′-(7-((1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0320] This compound was prepared using a procedure similar to that described for Example 1, Step 13, replacing (R)-5-formyl-2-(3′-(7-((1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Step 2) with (S)-5-formyl-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 41 H 43 N8O4(M+H) + Calculated value: m / z = 711.3; Found: 711.3.
[0321] Example 5
[0322] (S)-1-((7-cyano-2-(3′-(7-((2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0323]
[0324] Step 1: (S)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methylamino)propan-2-ol
[0325]
[0326] This compound was prepared using a procedure similar to that described for Example 1, Step 11, substituting (S)-1-aminopropan-2-ol for (R)-pyrrolidin-3-ol. LC-MS C 19 H 23 ClN5O(M+H) + Calculated value: m / z = 372.2; Found 372.2.
[0327] Step 2: (S)-5-Formyl-2-(3′-(7-((2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile
[0328]
[0329] This compound was prepared using a procedure analogous to that described for Example 1, Step 12, substituting (S)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methylamino)propan-2-ol (Step 1) for (R)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methyl)pyrrolidin-3-ol. LC-MS C 35 H 32 N7O3(M+H) + Calculated value: m / z = 598.3; Found 598.3.
[0330] Step 3: (S)-1-((7-cyano-2-(3′-(7-((2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0331] This compound was prepared using a procedure similar to that described for Example 1, Step 13, replacing (R)-5-formyl-2-(3′-(7-((2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Step 2) with (S)-5-formyl-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 41 H 43 N8O4(M+H) + Calculated value: m / z = 711.3; Found: 711.3.
[0332] Example 6
[0333] (R)-1-((7-cyano-2-(3′-(7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0334]
[0335] A mixture of (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile (Example 1, Step 12: 16 mg, 0.026 mmol), (R)-pyrrolidine-3-carboxylic acid (6.0 mg, 0.052 mmol) and triethylamine (7.3 μL, 0.052 mmol) in DCM (500 μL) was stirred at room temperature for 2 hours. Sodium triacetoxyborohydride (16.69 mg, 0.079 mmol) was then added. The mixture was further stirred at room temperature for 1 hour. The reaction mixture was diluted in MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MSC 41 H 41 N8O4(M+H) + Calculated value: m / z = 709.3; Found: 709.3.
[0336] Example 7
[0337] (R)-1-((7-cyano-2-(3′-(7-(((R)-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0338]
[0339] This compound was prepared using a procedure similar to that described for Example 6, replacing (R)-5-formyl-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Example 2, Step 2) with (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MSC 42 H 43 N8O4(M+H) + Calculated value: m / z = 723.3; Found: 723.3.
[0340] Example 8
[0341] (R)-1-((7-cyano-2-(3′-(7-(((S)-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0342]
[0343] This compound was prepared using a procedure similar to that described for Example 6, replacing (R)-5-formyl-2-(3′-((7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Example 3, Step 2) with (S)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MSC 42 H 43 N8O4(M+H) + Calculated value: m / z = 723.3; Found: 723.3.
[0344] Example 9
[0345] (R)-1-((7-cyano-2-(3′-(7-(((S)-1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0346]
[0347] This compound was prepared using a procedure similar to that described for Example 6, replacing (R)-5-formyl-2-(3′-((7-((1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Example 4, Step 2) with (S)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 40 H 41 N8O4(M+H) + Calculated value: m / z = 697.3; Found 697.3.
[0348] Example 10
[0349] (R)-1-((7-cyano-2-(3′-(7-(((S)-2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0350]
[0351] This compound was prepared using a procedure similar to that described for Example 6, replacing (R)-5-formyl-2-(3′-((7-((2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Example 5, Step 2) with (S)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 40 H 41 N8O4(M+H) + Calculated value: m / z = 697.3; Found 697.3.
[0352] Embodiment 11
[0353] (R)-1-((7-cyano-2-(3′-(7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid
[0354]
[0355] A mixture of (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile (Example 1, Step 12: 16 mg, 0.026 mmol), (R)-3-methylpyrrolidine-3-carboxylic acid (6.8 mg, 0.052 mmol) and triethylamine (7.3 μL, 0.052 mmol) in DCM (500 μL) was stirred at room temperature for 2 hours. Sodium triacetoxyborohydride (16.7 mg, 0.079 mmol) was then added. The mixture was further stirred at room temperature for 1 hour. The reaction mixture was diluted in MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MSC 42 H 43 N8O4(M+H) + Calculated value: m / z = 723.3; Found: 723.3. 1H NMR (600MHz, DMSO) δ9.87 (s, 1H), 8.77 (d, J = 1.7Hz, 1H), 8.15 (d, J = 7.3Hz, 1H), 8.10 (s, 1H), 7.95 (s, 1H), 7.90-7.81 (m, 2H), 7.55 (t, J = 7 .7Hz, 1H), 7.44 (d, J=6.9Hz, 1H), 7.36 (t, J=7.8Hz, 1H), 7.06 (d, J=7.3Hz, 1H), 4.21 (dt, J=6.3, 3.6Hz, 1H), 3.87-3.80 (m, 1H), 3.79-3.7 2 (m, 2H), 3.72-3.66 (m, 1H), 2.92 (d, J=9.1Hz, 1H), 2.71 (dd, J=9.6, 6.1Hz, 1H), 2.65 (q, J=8.0Hz, 1H), 2.62-2.54 (m, 2H), 2.48-2.46 (m, 6H), 2.46-2.43 (m, 1H), 2.38 (dd, J=9.6, 3.5Hz, 1H), 2.33-2.26 (m, 2H), 2.05-1.99 (m, 1H), 1.98 (s, 3H), 1.60-1.50 (m, 2H), 1.24 (s, 3H).
[0356] Example 12
[0357] (R)-1-((7-cyano-2-(3′-(7-(((R)-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid
[0358]
[0359] This compound was prepared using a procedure similar to that described for Example 11, replacing (R)-5-formyl-2-(3′-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Example 2, Step 2) with (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MSC43 H 45 N8O4(M+H) + Calculated value: m / z = 737.4; Found: 737.4.
[0360] Embodiment 13
[0361] (R)-1-((7-cyano-2-(3′-(7-(((S)-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid
[0362]
[0363] This compound was prepared using a procedure similar to that described for Example 11, replacing (R)-5-formyl-2-(3′-((7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Example 3, Step 2) with (S)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MSC 43 H 45 N8O4(M+H) + Calculated value: m / z = 737.4; Found: 737.4.
[0364] Embodiment 14
[0365] (R)-1-((7-cyano-2-(3′-(7-(((S)-1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid
[0366]
[0367] This compound was prepared using a procedure analogous to that described for Example 11, replacing (R)-5-formyl-2-(3′-((7-((1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Example 4, Step 2) with (S)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 41 H 43 N8O4(M+H) + Calculated value: m / z = 711.3; Found: 711.3.
[0368] Embodiment 15
[0369] (R)-1-((7-cyano-2-(3′-(7-(((S)-2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid
[0370]
[0371] This compound was prepared using a procedure similar to that described for Example 11, replacing (R)-5-formyl-2-(3′-((7-((2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Example 5, Step 2) with (S)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 41 H 43 N8O4(M+H) + Calculated value: m / z = 711.3; Found: 711.3.
[0372] Example 16
[0373] (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0374]
[0375] Step 1: 7-Bromo-2-(difluoromethyl)-4H-pyrido[3,2-d][1,3]oxazin-4-one
[0376]
[0377] A mixture of 3-amino-5-bromopicolinic acid (PharmBlock catalog number PB0554: 645 mg, 2.97 mmol) and 2,2-difluoroacetic anhydride (4.14 g, 23.8 mmol) was stirred at 60°C for 3 hours. After cooling to room temperature, the volatiles were removed by rotary evaporator and high vacuum pump. The residue was used directly in the next step. LC-MS C8H4BrF2N2O2 (M+H) + Calculated value: m / z = 276.9; found value 277.0.
[0378] Step 2: 7-Bromo-2-(difluoromethyl)pyrido[3,2-d]pyrimidin-4-ol
[0379]
[0380] A mixture of 7-bromo-2-(difluoromethyl)-4H-pyrido[3,2-d][1,3]oxazin-4-one (801 mg, 2.89 mmol) and aqueous ammonium hydroxide solution (8.0 ml, 28%) in a thick-walled glass tube was sealed and stirred at 85°C for 2 hours. After cooling to room temperature, the solution was then evaporated and the residue was rediluted with CH3CN and toluene. The suspension was evaporated again and the residue was used in the next step without further purification. LC-MS C8H5BrF2N3O (M+H) + Calculated value: m / z = 276.0; found value 276.0.
[0381] Step 3: 7-Bromo-N-(3-chloro-2-methylphenyl)-2-(difluoromethyl)pyrido[3,2-d]pyrimidin-4-amine
[0382]
[0383] To a mixture of 7-bromo-2-(difluoromethyl)pyrido[3,2-d]pyrimidin-4-ol (crude product from step 2: 750 mg, 2.72 mmol), benzyltriethylammonium chloride (1238 mg, 5.43 mmol) and N,N-diethylaniline (648 μl, 4.08 mmol) in acetonitrile (13.6 ml) was added phosphorus oxychloride (1.52 ml, 16.3 mmol). The mixture was stirred at 75° C. for 2 hours. The reaction was then cooled to room temperature. The volatiles were removed under reduced pressure.
[0384] To a solution of 3-chloro-2-methylaniline (409 mg, 2.89 mmol) and 7-bromo-4-chloro-2-(difluoromethyl)pyrido[3,2-d]pyrimidine (the above residue) in 2-propanol (14.4 ml) was added methanesulfonic acid (188 μl, 2.89 mmol). The mixture was stirred at 80 °C for 2 hours. The reaction was then cooled to room temperature. The mixture was carefully quenched by aqueous NaHCO3. The precipitate was filtered, washed with water and dried by air. The solid was used directly in the next step. LC-MS C 15 H 11 BrClF2N4(M+H) + Calculated value: m / z = 399.0; found value 399.0.
[0385] Step 4: N-(3-chloro-2-methylphenyl)-2-(difluoromethyl)-7-vinylpyrido[3,2-d]pyrimidin-4-amine
[0386]
[0387] A mixture of 7-bromo-N-(3-chloro-2-methylphenyl)-2-(difluoromethyl)pyrido[3,2-d]pyrimidin-4-amine (841 mg, 2.10 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (537 μl, 3.16 mmol), tetrakis(triphenylphosphine)palladium(0) (243 mg, 0.21 mmol) and potassium phosphate (1117 mg, 5.26 mmol) in tert-butyl alcohol (7.0 ml) and water (7.0 ml) was purged with N2 and then stirred at 100°C for 3 hours. The reaction was cooled to room temperature. The reaction mixture was diluted with water and extracted with DCM. The organic layer was dried over MgSO4, filtered and concentrated to give a crude residue which was purified by flash chromatography (0-30% EtOAc / DCM). LC-MS C 17 H 14 ClF2N4(M+H) + Calculated value: m / z = 347.1; found value 347.1.
[0388] Step 5: 4-(3-chloro-2-methylphenylamino)-2-(difluoromethyl)pyrido[3,2-d]pyrimidine-7-carbaldehyde
[0389]
[0390] A vial was charged with N-(3-chloro-2-methylphenyl)-2-(difluoromethyl)-7-vinylpyrido[3,2-d]pyrimidin-4-amine (195 mg, 0.562 mmol), THF (4.5 ml), a stirring bar and water (1.1 ml). To this solution was added sodium periodate (601 mg, 2.81 mmol) followed by osmium tetroxide (4% w / w in water, 221 μl, 0.028 mmol). After stirring at room temperature for 1 hour, the reaction was quenched with saturated aqueous sodium thiosulfate. The mixture was then extracted with DCM and the combined organic layers were washed with water, brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude residue was used directly in the next step without further purification. LC-MS C 16 H 12 Calculated value for ClF2N4O (M+H)+: m / z=349.1; found value 349.1.
[0391] Step 6: (R)-1-((4-(3-chloro-2-methylphenylamino)-2-(difluoromethyl)pyrido[3,2-d]pyrimidin-7-yl)methyl)pyrrolidin-3-ol
[0392]
[0393] A mixture of 4-((3-chloro-2-methylphenyl)amino)-2-(difluoromethyl)pyrido[3,2-d]pyrimidine-7-carbaldehyde (101 mg, 0.290 mmol) and (R)-pyrrolidin-3-ol (30.3 mg, 0.348 mmol) in DCM (1931 μl) was stirred at room temperature for 30 minutes. Sodium triacetoxyborohydride (92 mg, 0.434 mmol) was then added. The mixture was further stirred at room temperature for 1 hour. The reaction was quenched with NH4OH aqueous solution and extracted with DCM. The organic phases were combined and dried over MgSO4. After filtration, the DCM solution was concentrated to a residue, which was purified by flash chromatography (0-12% MeOH / DCM). LC-MSC 20 H 21 ClF2N5O(M+H) + Calculated value: m / z = 420.1; found value 420.2.
[0394] Step 7: (R)-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)-5-formylbenzo[d]oxazole-7-carbonitrile
[0395]
[0396] (R)-1-((4-((3-chloro-2-methylphenyl)amino)-2-(difluoromethyl)pyrido[3,2-d]pyrimidin-7-yl)methyl)pyrrolidin-3-ol (34.4 mg, 0.082 mmol), 5-formyl-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazole-7-carbonitrile (Step 1 of Example 1) were added. A mixture of 7:35 mg, 0.090 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (6.5 mg, 8.2 μmol) and potassium phosphate (43.5 mg, 0.205 mmol) in water (140 μl) and 1,4-dioxane (690 μl) was purged with N2 and then sealed. The reaction was stirred at 100°C for 2 hours. The reaction was cooled to room temperature. The reaction mixture was diluted with DCM and H2O. The layers were separated. The aqueous layer was extracted three times with DCM. The organic layer was dried over MgSO4, filtered and concentrated to give a crude residue which was used directly in the next step without further purification. LC-MS C 36 H 30 F2N7O3(M+H) + Calculated value: m / z = 646.2; found value 646.3.
[0397] Step 8: (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0398] A mixture of (R)-2-(3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-5-formylbenzo[d]oxazole-7-carbonitrile (9.5 mg, 0.015 mmol) and tert-butyl piperidine-4-carboxylate (5.45 mg, 0.029 mmol) was stirred at room temperature for 2 hours. Sodium triacetoxyborohydride (9.36 mg, 0.044 mmol) was then added. The mixture was stirred at room temperature for 1 hour. Trifluoroacetic acid (300 μL) was then added to the mixture and stirred for 30 minutes. The volatiles were evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MSC 42 H 41 F2N8O4(M+H) + Calculated value: m / z = 759.3; found value 759.6. 1 H NMR (500MHz, DMSO) δ10.63 (s, 1H), 9.13 (s, 1H), 8.52 (d, J = 2.0Hz, 1H), 8.39 (d, J = 1.6Hz, 1H), 8.19 (dd, J = 7.9, 1.5Hz, 1H), 8.11 (d, J=2.1Hz, 1H), 7.64 (dd, J=8.1, 1.3Hz, 1H), 7.59 (t, J=7.7Hz, 1H), 7.49 (dd, J=7.5, 1.5Hz, 1H), 7.41 (t, J=7.8Hz, 1H), 7.16 (dd, J=7.6, 1.3Hz, 1H), 6.74 (t, J=54.5Hz, 1H), 4.85-4.65 (m, 2H), 4.58-4.40 (m, 3H), 3.74-3.00 (m, 8H), 2.78-2.54 (m, 1H), 2.50 (s, 3H), 2.32-1.91 (m, 5H), 1.95 (s, 3H), 1.79-1.67 (m, 1H).
[0399] Embodiment 17
[0400] (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0401]
[0402] This compound was prepared using a procedure analogous to that described for Example 6, replacing (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile (Example 16, Step 7) with (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 41 H 39 F2N8O4(M+H) + Calculated value: m / z = 745.3; Found: 745.3.
[0403] Embodiment 18
[0404] (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid
[0405]
[0406] This compound was prepared using a procedure analogous to that described for Example 11, replacing (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile (Example 16, Step 7) with (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 42 H 41 F2N8O4(M+H) +Calculated value: m / z = 759.3; found value 759.6.
[0407] Embodiment 19
[0408] (R)-1-((7-cyano-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0409]
[0410] Step 1: (R)-5-Formyl-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile
[0411]
[0412] This compound was prepared using a procedure similar to that described for Example 16 (steps 1-7), substituting trifluoroacetic anhydride for 2,2-difluoroacetic anhydride in step 1. LC-MS C 36 H 29 F3N7O3(M+H) + Calculated value: m / z = 664.2; Found 664.2.
[0413] Step 2: (R)-1-((7-cyano-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0414] This compound was prepared using a procedure similar to that described for Example 1, Step 13, replacing (R)-5-formyl-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Step 1) with (R)-5-formyl-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C42 H 40 F3N8O4(M+H) + Calculated value: m / z = 777.3; Found: 777.3.
[0415] Embodiment 20
[0416] (R)-1-((7-cyano-2-(3′-(7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0417]
[0418] This compound was prepared using a procedure similar to that described for Example 6, replacing (R)-5-formyl-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Example 19, Step 1) with (R)-5-formyl-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 41 H 38 F3N8O4(M+H) + Calculated value: m / z = 763.3; Found: 763.3.
[0419] Embodiment 21
[0420] (R)-1-((7-cyano-2-(3′-(7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid
[0421]
[0422] This compound was prepared using a procedure similar to that described for Example 11, replacing (R)-5-formyl-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (Example 19, Step 1) with (R)-5-formyl-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 42 H 40 F3N8O4(M+H) + Calculated value: m / z = 777.3; Found: 777.3.
[0423] Embodiment 22
[0424] (S)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0425]
[0426] This compound was prepared using a procedure analogous to that described for Example 6, substituting (S)-pyrrolidine-3-carboxylic acid for (R)-pyrrolidine-3-carboxylic acid and (R)-2-(3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-5-formylbenzo[d]oxazole-7-carbonitrile (Example 16, Step 7) for (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 41 H 39 F2N8O4(M+H) +Calculated value: m / z = 745.3; Found: 745.3.
[0427] Embodiment 23
[0428] (S)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid
[0429]
[0430] This compound was prepared using a procedure analogous to that described for Example 6, substituting (S)-3-methylpyrrolidine-3-carboxylic acid for (R)-pyrrolidine-3-carboxylic acid and (R)-2-(3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-5-formylbenzo[d]oxazole-7-carbonitrile (Example 16, Step 7) for (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 42 H 41 F2N8O4(M+H) + Calculated value: m / z = 759.3; Found: 759.3.
[0431] Embodiment 24
[0432] (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-4-methylpiperidine-4-carboxylic acid
[0433]
[0434] This compound was prepared using a procedure similar to that described for Example 16, substituting tert-butyl 4-methylpiperidine-4-carboxylate for tert-butyl piperidine-4-carboxylate in step 8. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MSC 43 H 43 F2N8O4(M+H) + Calculated value: m / z = 773.3; Found: 773.3.
[0435] Embodiment 25
[0436] (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-N,N-dimethylpiperidine-4-carboxamide
[0437]
[0438] To a solution of (R)-1-((7-cyano-2-(3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid (Example 16: 7.0 mg, 9.22 μmol), dimethylamine (2.0 M methanol solution, 0.014 ml) and N,N-diisopropylethylamine (5 μl, 0.028 mmol) in DMF (0.3 ml) was added HATU (7.0 mg, 0.018 mmol). After stirring at room temperature for 2 hours, the reaction mixture was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 44 H 46 F2N9O3(M+H) + Calculated value: m / z = 786.4; Found: 786.4.
[0439] Embodiment 26
[0440] (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-N-methylpiperidine-4-carboxamide
[0441]
[0442] This compound was prepared using a procedure similar to that described for Example 25, substituting methylamine solution for dimethylamine solution. The reaction mixture was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 43 H 44 F2N9O3(M+H) + Calculated value: m / z = 772.4; found value 772.3.
[0443] Embodiment 27
[0444] (R)-3-(1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidin-4-carboxamido)propanoic acid
[0445]
[0446] This compound was prepared using a procedure similar to that described for Example 25, substituting tert-butyl 3-aminopropionate for the dimethylamine solution. After the amide bond was formed, the reaction mixture was treated with trifluoroacetic acid (0.5 mL) and stirred at room temperature for 1 hour. The reaction mixture was then concentrated, redissolved in MeOH and then purified by preparative HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. LC-MS C 45 H 46 F2N9O5(M+H) + Calculated value: m / z = 830.4; found value 830.3.
[0447] Embodiment 28
[0448] (R)-1-((7-cyano-2-(3′-(2-cyclopropyl-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0449]
[0450] Step 1: (R)-2-(3′-(2-cyclopropyl-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)-5-formylbenzo[d]oxazole-7-carbonitrile
[0451]
[0452] This compound was prepared using a procedure analogous to that described for Example 16 (steps 1-7), substituting cyclopropanecarboxylic anhydride for 2,2-difluoroacetic anhydride in step 1. LC-MS C 38 H 34 N7O3(M+H) + Calculated value: m / z = 636.3; found value 636.4.
[0453] Step 2: (R)-1-((7-cyano-2-(3′-(2-cyclopropyl-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0454] This compound was prepared using a procedure similar to that described for Example 6, replacing (R)-5-formyl-2-(3′-(7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)-5-formylbenzo[d]oxazole-7-carbonitrile (step 1) with (R)-2-(3′-(2-cyclopropyl-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 43 H 43 N8O4(M+H) + Calculated value: m / z = 735.3; Found: 735.3.
[0455] Embodiment 29
[0456] (R)-1-((2-(3′-(2-amino-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)-7-cyanobenzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0457]
[0458] Step 1: N-(7-bromo-4-oxo-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)acetamide
[0459]
[0460] A mixture of 3-amino-5-bromopicolinamide (1.88g, 8.70mmol) and carbamoyl chloride hydrochloride (1.30g, 11.31mmol) in sulfolane (5.44ml) and dimethyl sulfone (5.44ml) was stirred at 165°C for 5 hours in a sealed vial. After cooling to room temperature, the reaction was carefully diluted with water to form a suspension. The precipitate was collected by filtration and washed with water. The solid was dried in air and used directly without further purification. A mixture of the above solid (685mg, 2.84mmol) and acetic anhydride (13.4ml) was stirred at 115°C for 8 hours. After cooling to room temperature, the mixture was diluted with DCM and washed with water. The organic layer was dried over MgSO4, filtered and concentrated to give a crude material, which was used directly in the next step. LC-MSC9H8BrN4O2(M+H) + Calculated value: m / z = 283.0; found value 283.0.
[0461] Step 2: 7-Bromo-N 4 -(3-chloro-2-methylphenyl)pyrido[3,2-d]pyrimidine-2,4-diamine
[0462]
[0463] To a mixture of N-(7-bromo-4-oxo-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)acetamide (201 mg, 0.710 mmol), benzyltriethylammonium chloride (323 mg, 1.420 mmol) and N,N-diethylaniline (169 μl, 1.065 mmol) in acetonitrile (3.5 ml) was added POCl (397 μl, 4.26 mmol). The mixture was stirred at 75° C. for 2 hours. The reaction was then cooled to room temperature. The volatiles were removed under reduced pressure.
[0464] To a solution of 3-chloro-2-methylaniline (100 mg, 0.710 mmol) and N-(7-bromo-4-chloropyrido[3,2-d]pyrimidin-2-yl)acetamide (the above residue) in 2-propanol (3549 μl) was added methanesulfonic acid (46.1 μl, 0.710 mmol). The mixture was stirred at 80°C for 2 hours. The reaction was then cooled to room temperature. The mixture was carefully quenched by aqueous NaHCO3 solution. The precipitate was filtered, washed with water and dried by air. The solid was used directly in the next step. LC-MSC 14 H 12 BrClN5(M+H) + Calculated value: m / z = 364.0; found value 364.0.
[0465] Step 3: (R)-1-((2-amino-4-(3-chloro-2-methylphenylamino)pyrido[3,2-d]pyrimidin-7-yl)methyl)pyrrolidin-3-ol
[0466]
[0467] This compound was prepared using a procedure similar to that described for Example 16 (steps 4-6) using 7-bromo-N 4 -(3-chloro-2-methylphenyl)pyrido[3,2-d]pyrimidine-2,4-diamine was prepared instead of 7-bromo-N-(3-chloro-2-methylphenyl)-2-(difluoromethyl)pyrido[3,2-d]pyrimidin-4-amine. LC-MS C 19 H 22 ClN6O(M+H) + Calculated value: m / z = 385.2; Found value 385.2.
[0468] Step 4: tert-Butyl 1-((7-cyano-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylate
[0469]
[0470] A mixture of 5-formyl-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazole-7-carbonitrile (Example 1 Step 7: 684 mg, 1.76 mmol) and tert-butyl piperidine-4-carboxylate (392 mg, 2.11 mmol) in DCM (7.0 ml) was stirred at room temperature for 2 hours. Sodium triacetoxyborohydride (560 mg, 2.64 mmol) was then added. The mixture was further stirred at room temperature for 1 hour. The reaction was quenched with aqueous NH4OH and extracted by DCM. The organic phases were combined and dried over MgSO4. After filtration, the DCM solution was concentrated to a residue, which was purified by flash chromatography (0-20% EtOAc / hexanes). LC-MS C 32 H 41 BN3O5(M+H) + Calculated value: m / z = 558.3; Found 558.3.
[0471] Step 5: (R)-1-((2-(3′-(2-amino-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)-7-cyanobenzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0472] (R)-1-((2-amino-4-((3-chloro-2-methylphenyl)amino)pyrido[3,2-d]pyrimidin-7-yl)methyl)pyrrolidin-3-ol (33.9 mg, 0.088 mmol), tert-butyl 1-((7-cyano-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylate ( A mixture of 2-(4-(2-(2-(2-(2-(2-(2-(2-(2-(2-((-1-(-dioxane (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( After stirring at room temperature for 30 minutes, the reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 41 H 42 N9O4(M+H) + Calculated value: m / z = 724.3; found value 724.4.
[0473] Embodiment 30
[0474] (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0475]
[0476] Step 1: (R)-1-((4-(3-chloro-2-methylphenylamino)-2-(difluoromethyl)pyrido[3,2-d]pyrimidin-7-yl)methyl)-3-methylpyrrolidin-3-ol
[0477]
[0478] This compound was prepared using a procedure similar to that described for Example 16, Step 6, substituting (R)-3-methylpyrrolidin-3-ol for (R)-pyrrolidin-3-ol. LC-MS C 21 H 23 ClF2N5O(M+H) + Calculated value: m / z = 434.2; Found: 434.2.
[0479] Step 2: (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0480] This compound was prepared using a procedure similar to that described for Example 29, replacing (R)-1-((4-(3-chloro-2-methylphenylamino)-2-(difluoromethyl)pyrido[3,2-d]pyrimidin-7-yl)methyl)-3-methylpyrrolidin-3-ol (step 1) in step 5. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. LC-MS C 43 H 43 F2N8O4(M+H) + Calculated value: m / z = 773.3; Found: 773.3.
[0481] Embodiment 31
[0482] (S)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0483]
[0484] This compound was prepared using a procedure similar to that described for Example 30, substituting (S)-3-methylpyrrolidin-3-ol for (R)-3-methylpyrrolidin-3-ol. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MSC 43 H43 F2N8O4(M+H) + Calculated value: m / z = 773.3; Found: 773.3.
[0485] Embodiment 32
[0486] (R)-1-((7-cyano-2-(3′-(2-(hydroxymethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0487]
[0488] Step 1: 7-Bromo-2-(hydroxymethyl)pyrido[3,2-d]pyrimidin-4(3H)-one
[0489]
[0490] To a solution of 3-amino-5-bromopicolinamide (142mg, 0.657mmol) in THF was added 2-chloro-2-oxoethyl acetate (90mg, 0.66mmol) at 0°C. The mixture was stirred at room temperature until LCMS showed that the reaction was complete. Water was then slowly added to the mixture. The precipitate was filtered and collected, washed with a small amount of water and CH3CN. After air drying, the solid was used directly.
[0491] A mixture of the above solid and ammonium hydroxide (aqueous solution, 28%, 1.7 ml, 12.04 mmol) in a thick glass tube was stirred at 85°C for 2 hours. After cooling to room temperature, the solution was evaporated and the residue was rediluted with CH3CN and toluene. The suspension was evaporated again and the residue was used in the next step without further purification. LC-MS C8H7BrN3O2 (M+H) + Calculated value: m / z = 256.0; found value 256.1.
[0492] Step 2: 7-Bromo-2-((tert-butyldimethylsilyloxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one
[0493]
[0494] To a solution of 7-bromo-2-(hydroxymethyl)pyrido[3,2-d]pyrimidin-4(3H)-one (185 mg, 0.722 mmol) and imidazole (73.8 mg, 1.084 mmol) in DMF (4817 μl) was added tert-butyldimethylsilyl chloride (120 mg, 0.795 mmol). The mixture was stirred at room temperature for 2 hours. The mixture was then concentrated and the residue was purified by flash chromatography (0-20% EtOAc / hexanes) to give the desired product. LC-MS C 14 H 21 BrN3O2Si(M+H) + Calculated value: m / z = 370.1; found value 370.1.
[0495] Step 3: 7-Bromo-2-((tert-butyldimethylsilyloxy)methyl)-N-(3-chloro-2-methylphenyl)pyrido[3,2-d]pyrimidin-4-amine
[0496]
[0497] To a mixture of 7-bromo-2-((tert-butyldimethylsilyloxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one (201mg, 0.54mmol) and DIEA (190μl, 1.09mmol) in DCM (2.2ml) was added methanesulfonyl chloride (85μl, 1.09mmol) at 0°C. The mixture was stirred at room temperature for 3 hours. 3-chloro-2-methylaniline (100mg, 0.71mmol) was then added to the mixture and the corresponding mixture was further stirred at room temperature overnight. The mixture was diluted with DCM and then washed with water. The DCM solution was dried over MgSO4 and filtered. The filtrate was concentrated. The residue was purified by flash chromatography (0-40% EtOAc / hexane). LC-MS C 21 H 27 BrClN4OSi(M+H) + Calculated value: m / z = 493.1; found value 493.1.
[0498] Step 4: (R)-1-((2-(3′-(2-((tert-butyldimethylsilyloxy)methyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)-7-cyanobenzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0499]
[0500] This compound was prepared using a procedure similar to that described for Example 1 (steps 9-13), substituting 7-bromo-2-((tert-butyldimethylsilyloxy)methyl)-N-(3-chloro-2-methylphenyl)pyrido[3,2-d]pyrimidin-4-amine (step 3) for 7-bromo-N-(3-chloro-2-methylphenyl)-2-methylpyrido[3,2-d]pyrimidin-4-amine. Upon completion, the reaction solution was used directly in the next step. LC-MS C 48 H 57 N8O5Si(M+H) + Calculated value: m / z = 853.4; Found 853.4.
[0501] Step 5: (R)-1-((7-cyano-2-(3′-(2-(hydroxymethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid
[0502] To the above reaction solution (step 4) was added triethylamine trihydrofluoride (411 μl, 60 equivalents) at room temperature. The mixture was further stirred at this temperature for 1 hour. The reaction mixture was then concentrated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product in the form of a TFA salt. LC-MSC 42 H 43 N8O5(M+H) + Calculated value: m / z = 739.3; found value 739.5.
[0503] Embodiment 33
[0504] (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6-methyl-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0505]
[0506] Step 1: 5-Bromo-N-tert-butyl-3-(2-oxopropyl)picolinamide
[0507]
[0508] At -40 ° C under N2 atmosphere, butyl lithium (2.5M hexane, 12.79ml, 32.0mmol) was added to a solution of diisopropylamine (3.42ml, 24.0mmol) in THF (10mL). The mixture was stirred at this temperature for 5 minutes. Then a solution of 5-bromo-N-(tert-butyl)-3-methylpicolinamide (2.71g, 10.0mmol) in THF (2mL) was added. The reaction was stirred at -40 ° C for 30 minutes, then warmed to -10 ° C. Then, at -40 ° C, the above mixture was added to THF (6mL) containing ethyl acetate (1.17ml, 12.0mmol) under stirring. After addition, the reaction was further stirred and slowly warmed to -10 ° C. Then the reaction was quenched by adding NH4Cl aqueous solution. Then the mixture was extracted three times with DCM. The organic phase was combined and dried over MgSO4 and filtered. The filtrate was concentrated and the residue was purified by flash chromatography using EtOAc / hexanes (0-25%) to give the desired product. LC-MS C 13 H 18 BrN2O2(M+H) + Calculated value: m / z = 313.1; Found 313.1.
[0509] Step 2: 3-Bromo-6-methyl-1,7-naphthyridin-8-ol
[0510]
[0511] A mixture of 5-bromo-N-(tert-butyl)-3-(2-oxopropyl)picolinamide (716 mg, 2.29 mmol) and ammonium acetate (1762 mg, 22.86 mmol) in acetic acid (1.8 ml) was heated to 108°C and stirred at this temperature for 12 hours. The reaction was allowed to cool to room temperature. Water was added and a precipitate formed. The suspension was filtered and the solid collected for direct use. LC-MS C9H8BrN2O (M+H) + Calculated value: m / z = 239.0; found value 239.1.
[0512] Step 3: (R)-1-((8-(3-chloro-2-methylphenylamino)-6-methyl-1,7-naphthyridin-3-yl)methyl)pyrrolidin-3-ol
[0513]
[0514] This compound was prepared using a procedure analogous to that described for Example 16 (steps 3-6), substituting 3-bromo-6-methyl-1,7-naphthyridin-8-ol (step 2) for 7-bromo-2-(difluoromethyl)pyrido[3,2-d]pyrimidin-4-ol. LC-MSC 21 H24 ClN4O(M+H) + Calculated value: m / z = 383.2; found value 383.3.
[0515] Step 4: (R)-5-Formyl-2-(3′-(3-((3-hydroxypyrrolidin-1-yl)methyl)-6-methyl-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile
[0516]
[0517] This compound was prepared using a procedure analogous to that described for Example 1, Step 12, substituting (R)-1-((8-(3-chloro-2-methylphenylamino)-6-methyl-1,7-naphthyridin-3-yl)methyl)pyrrolidin-3-ol (Step 3) for (R)-1-((4-(3-chloro-2-methylphenylamino)-2-methylpyrido[3,2-d]pyrimidin-7-yl)methyl)pyrrolidin-3-ol. LC-MSC 37 H 33 N6O3(M+H) + Calculated value: m / z = 609.3; found value 609.4.
[0518] Step 5: (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6-methyl-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0519] This compound was prepared using a procedure similar to that described for Example 6, replacing (R)-5-formyl-2-(3′-(3-((3-hydroxypyrrolidin-1-yl)methyl)-6-methyl-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazole-7-carbonitrile (step 4) with (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 42 H 42 N7O4(M+H) + Calculated value: m / z = 708.3; Found 708.3.
[0520] Embodiment 34
[0521] (R)-1-((7-cyano-2-(3′-(6-(difluoromethyl)-3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid
[0522]
[0523] Step 1: (R)-2-(3′-(6-(difluoromethyl)-3-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)-5-formylbenzo[d]oxazole-7-carbonitrile
[0524]
[0525] This compound was prepared using a procedure similar to that described for Example 33 (steps 1-4) using methyl 2,2-difluoroacetate instead of ethyl acetate. LC-MS C 37 H 31 F2N6O3(M+H) + Calculated value: m / z = 645.2; Found 645.2.
[0526] Step 2: (R)-1-((7-cyano-2-(3′-(6-(difluoromethyl)-3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid
[0527] This compound was prepared using a procedure analogous to that described for Example 11, replacing (R)-5-formyl-2-(3′-((7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazole-7-carbonitrile (step 1) with (R)-2-(3′-(6-(difluoromethyl)-3-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)-5-formylbenzo[d]oxazole-7-carbonitrile. The reaction mixture was evaporated and the residue was diluted with MeOH and then purified by preparative HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. LC-MS C 43 H 42 F2N7O4(M+H)+ Calculated value: m / z = 758.3; Found: 758.3.
[0528] Example A. Homogeneous Time-Resolved Fluorescence (HTRF) PD-1 / PD-L1 Binding Assay
[0529] The assay was performed in a standard black 384-well polystyrene plate with a final volume of 20 μL. The inhibitor was first serially diluted in DMSO and then added to the plate wells, followed by the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was performed in PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA at 25°C. Recombinant human PD-L1 protein (19-238) with a His tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with an Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in assay buffer and 10 μL were added to the plate wells. The plate was centrifuged and the protein was incubated with the inhibitor for 40 minutes. After incubation, 10 μL of anti-human IgG (PerkinElmer-AD0212) labeled with europium cryptate specific for Fc and bound to -HTRF detection buffer with anti-His antibody against allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plates were incubated at 25°C for 60 minutes and then read on a PHERAstar FS plate reader (665nm / 620nm ratio). The final concentrations in the assay were: 3nM PD1, 10nM PD-L1, 1nM Europium anti-human IgG and 20nM anti-His-allophycocyanin. IC was determined by fitting a curve of percentage of control activity versus log of inhibitor concentration using GraphPad Prism 5.0 software. 50 .
[0530] Example B. Src homology 2 domain containing phosphatase (SHP) assay
[0531] U2OS / PD-L1 cells (DiscoveRx) were maintained in McCoy's 5A medium supplemented with 10% FBS and 0.25 μg / ml puromycin. After the medium was removed, the cell culture medium was replaced with assay medium (RPMI1640 medium with 1% FBS). U2OS / PD-L1 cells were then added to a 384-well black transparent bottom assay plate (5000 cells per well) in 20 μL assay medium. Tissue culture plates, Greiner Bio-One). Test compounds were prepared by serial dilution in DMSO and 125nL of the compound was first transferred to 384REMP plate wells (Thermofisher) by an ECHO liquid handler (Labcyte), followed by the addition of 27.5μL assay medium. 5μL / well compounds in the assay medium were transferred to a cell plate with 0.05% DMSO, and 0.25μM was measured in the final assay. Jurkat-PD-1-SHP cells (DiscoveRx) were cultured in RPMI1640 culture medium supplemented with 10% FBS, 250μg / ml hygromycin B, 500μg / ml G418. After replacing the culture medium with the assay medium, 5,000 Jurkat-PD-1-SHP cells in 20μL were distributed to each well. The assay plate was incubated at 37°C, 5% CO2 for 2 hours, followed by the addition of 2.5 μL PathHunter reagent 1 (DiscoveRx) to each well. The assay plate was shaken at 350 rpm for 1 minute in the dark, followed by the addition of 10 μL PathHunter reagent 2 (DiscoveRx). After incubation at room temperature for 1 hour, the chemiluminescent signal was recorded using a TopCount reader (PerkinElmer). Wells with DMSO were used as positive controls and wells without cells were used as negative controls. IC was determined by fitting a curve of control activity percentage relative to the log of compound concentration using GraphPad Prism 6.0 software. 50 .
[0532] Example C. Nuclear factor of activated T cells (NFAT) assay
[0533] PD-L1 aAPC / CHO-K1 cells (Promega) were maintained in F-12 medium supplemented with 10% FBS, 200 μg / ml hygromycin B, and 250 μg / ml geneticin (G418). Jurkat-PD-1-NFAT effector cells (Promega) were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 μg / ml hygromycin B, and 500 μg / ml G418. The culture medium of PD-L1aAPC / CHO-K1 cells was first replaced with assay medium (RPMI1640 medium with 1% FBS). PD-L1 aAPC / CHO-K1 cells were then added to a white 384-well white transparent bottom assay plate ( Tissue culture plates, Greiner Bio-One). Test compounds were prepared by serial dilution in DMSO and 0.8 μL of test compound in DMSO was first transferred to a 384REMP plate well (Thermofisher) by PlateMate Plus (Thermofisher), followed by the addition of 50 μL of plate culture medium. 5 μL of compound in the assay medium was transferred to cells with 0.4% DMSO, and the final assay was 2 μM. After removing the culture medium, 10,000 Jurkat-PD-1-NFAT effector cells in 5 μL of assay medium were distributed to each well. The assay plate was incubated at 37°C, 5% CO2 for 24 hours. After the assay plate was equilibrated to room temperature for 15 minutes, 20 μL / well Bio-Glo TM Reagent (Promega). After incubation at room temperature for 8 minutes, read fluorescence on a Pherastar microplate reader (BMG Labtech). Calculate the fold of induction (FOI) based on the luminescence ratio normalized to the DMSO wells in each assay plate. Report the maximum induction percentage based on the ratio of the highest FOI of each compound to the maximum FOI of the control compound in each assay plate. The wells with DMSO are used as negative controls and the wells containing the control compound with the highest FOI are used as positive controls. EC50 is determined by fitting the curve of the control activity percentage relative to the log of the compound concentration using GraphPad Prism 6.0 software.
[0534] Example D. PD-L1 whole blood internalization analysis
[0535] To determine PD-L1 internalization in human whole blood, normal human blood (Biological Specialty, Colmar.PA) was incubated in a 96-well "2ml assay blocking solution" (Corning, Corning NY) at 37°C in the presence or absence of a range of test compounds and 1ng / ml human interferon gamma (R&D Systems, Minn.MN) for 18-20 hours. The blood was then stained with PD-L1 (MIH1, eBioscience; or BD Biosciences SanJose, CA), CD14 (Life Technologies, Carlsbad, CA) for 30 minutes at room temperature in the dark. Whole blood / erythrocytes were lysed / fixed (lysis buffer, BD Biosciences) for 5 minutes at 37°C in the dark and then centrifuged at 1600RPM for 5 minutes. The cells were resuspended in staining buffer (BD Bioscience, San Jose, CA) and transferred to a 96-well round-bottom plate (Corning). Cells were gated based on CD14+ (BD Biosciences) and analyzed by mean fluorescence intensity (MFI) (BD LSRFortessa TM The IC was determined by fitting the curve of compound inhibition percentage against the log of compound concentration using GraphPad Prism 7.0 software. 50 .
[0536] Example E. In vivo pharmacokinetics in rats, monkeys and dogs
[0537] For in vivo pharmacokinetic experiments, test compounds were administered intravenously or via oral gavage to male Sprague Dawley rats, male beagle dogs, or female and male Cynomolgus monkeys. For IV administration, test compounds were administered at 0.5 to 1 mg / kg using a formulation of 10% dimethylacetamide (DMAC) in acidified saline, rats were given an IV bolus, and dogs and monkeys were given a 5-minute or 10-minute IV infusion, respectively. For oral administration, test compounds were administered at 1.0 to 3.0 mg / kg using 5% DMAC in citrate buffer (pH 3.5) containing 0.5% methylcellulose. Blood samples were collected before and at multiple time points up to 24 hours after administration. All blood samples were collected using EDTA as an anticoagulant and centrifuged to obtain plasma samples. Plasma concentrations of test compounds were determined by LC-MS. The concentrations were determined by standard non-compartmental methods using The WinNonlin software program (version 7.0, Pharsight) was used to calculate PK parameters using the measured plasma concentrations.
[0538] In rats and monkeys, cassette dosing of up to six test compounds was performed to obtain preliminary PK parameters.
[0539] Example F. Results
[0540] Compounds of the present disclosure as exemplified in Examples 1-34 were evaluated in each of the HTRF PD-1 / PD-L1 binding assay (Example A), SHP assay (Example B), NFAT assay (Example C), and whole blood internalization assay (Example D). Cutoff values for the range of values observed in each analysis are shown. The results obtained for the tested compounds are shown in Table 1.
[0541]
[0542] Table 1
[0543]
[0544]
[0545] In addition to what is described herein, various modifications of the present invention will be apparent to those skilled in the art from the above description. It is also intended that such modifications are within the scope of the appended claims. Each reference cited in this application, including but not limited to all patents, patent applications and publications, is incorporated herein by reference in its entirety.
Claims
1. A compound selected from: (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid; (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid; (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid; and (S)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid; or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, which is (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2, which is (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.
4. The compound according to claim 1, which is (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 4, which is (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid.
6. The compound according to claim 1, which is (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 6, which is (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid.
8. The compound according to claim 1, which is (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 8, which is (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.
10. The compound according to claim 1, which is (S)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 10, which is (S)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.
12. A pharmaceutical composition comprising a compound according to any one of claims 1-2, 4, 6, 8 or 10 or a pharmaceutically acceptable salt thereof or a compound according to any one of claims 3, 5, 7, 9 or 11 and a pharmaceutically acceptable excipient or carrier.
